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a b s t r a c t
Background: Borna disease virus (BDV) is a neurotropic RNA virus persistently infecting mammalian
hosts including humans. Lysine acetylation (Kac) is a key protein post-translational modiﬁcation (PTM).
The unexpectedly broad regulatory scope of Kac let us to proﬁle the entire acetylome upon BDV infection.
Methods: The acetylome was proﬁled through stable isotope labeling for cell culture (SILAC)-based
quantitative proteomics. The quantiﬁable proteome was annotated using bioinformatics.
Results: We identiﬁed and quantiﬁed 791 Kac sites in 473 Kac proteins in human BDV Hu-H1-infected
and non-infected oligodendroglial (OL) cells. Bioinformatic analysis revealed that BDV infection alters the
acetylation of metabolic proteins, membrane-associated proteins and transmembrane transporter
activity, and affects the acetylation of several lysine acetyltransferases (KAT).
Conclusions: Upon BDV persistence the OL acetylome is manipulated towards higher energy and
transporter levels necessary for shuttling BDV proteins to and from nuclear replication sites.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Borna disease virus (BDVs) is the main genus of the family
Bornaviridae and persistently infects a wide variety of mammalian
host species. In contrast to all other members of the order
Mononegavirales, its non-segmented, negative- and single-
stranded (NNS) RNA genome replicates in the nucleus of infected
cells (de la Torre, 1994; Ludwig et al., 1988; Schneemann et al.,
1995). BDVs-infection may induce a large spectrum of neuropsy-
chiatric pathologies ranging from immune-mediated neurological
disease to non-inﬂammatory behavioral alterations (Hornig et al.,
2003; Ludwig and Bode, 2000; Zhang et al., 2014). According to
many disease patterns notably reminiscent of symptoms observed
in certain human neuropsychiatric disorders (Hornig et al., 2001),
infection in human psychiatric illness has been studied since three
decades, but the ﬁndings remain controversial (Bode and Ludwig,
2003; Bode et al., 1995; Hornig et al., 2012; Iwata et al., 1998; Rott
et al., 1985; Zhang et al., 2013). Notwithstanding, a few human
BDV strains have been isolated through co-cultivation of freshly
isolated white blood cells from German psychiatric inpatients with
a human fetal oligodendroglial cell line (OL cells) (Bode et al.,
1996). Genetic analysis has validated both the identity of the BDV
RNA in the original samples and the corresponding isolates as well
as their authenticity as human viruses, as these human strains
differ genetically from the laboratory reference strain V and
another lab strain termed C6BV by a few distinct mutations (de
la Torre et al., 1996). Moreover, our group has found that the
human BDV strain Hu-H1 inhibits proliferation and promotes
apoptosis of OL cells in vitro, while laboratory strain V displays
the opposite effects (Li et al., 2013).
Post-translational modiﬁcations (PTMs) regulate the functional
and physical properties of proteins in response to changes in external
conditions or internal states. Acetylation and phosphorylation are
supposed to be ancient conserved PTMs which occur ubiquitously
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across all domains of life (Beltrao et al., 2013) and have shown to be
intertwiningly related on a long timescale in evolution (Sabo et al.,
2008; van Noort et al., 2012). BDV is an evolutionarily very old virus
with a suggested co-evolution of more than 40 million years in
primate ancestor hosts up to humans (Horie et al., 2010). Whether
and to which extent an ancient neurotropic virus like BDV is able to
manipulate ancient PTMs of its host cells should improve our
understanding of how BDV impacts on neuropathogenesis.
Lysine acetylation (Kac) is a reversible PTM, initially discovered on
histones about four decades ago on account of their high abundance
Fig. 1. Experimental Workﬂow Whole-cell extracts were prepared from BDV-infected and non-infected control OL cells. Immunoprecipitation coupled with SILAC-based
quantitative proteomics was used to comparatively analyze the two groups followed by bioinformatical analysis.
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and frequency (Vidali et al., 1968). Over the last 10 years, improve-
ments in mass spectrometry (speciﬁcally, more accurate mass
detection, sensitivity and dynamic range, higher resolution, and
faster scan rates) serve to greatly facilitate global acetylation studies
(Mischerikow and Heck, 2011). As a result, Kac has been determined
to be involved in a wide range of functional roles, including DNA-
protein interaction, transcriptional activity, subcellular localization,
protein stability, and enzyme activation (Choudhary et al., 2009; Kim
et al., 2006a; Zhao et al., 2010). Moreover, Kac and its regulatory
enzymes (lysine acetyltransferases [KATs] and lysine deacetylases
[KDACs]) have been intimately linked to several major diseases,
including cancer, neurodegenerative disorders, and cardiovascular
disease (Carrozza et al., 2003; McKinsey and Olson, 2004; Michishita
et al., 2005; Yang, 2004).
Previous studies suggest that the spectrum of acetylated proteins
varies signiﬁcantly by cell type. For example, Zhao et al. (2010) has
discovered 1047 acetylated proteins in human liver cells, while
Choudhary et al. (2009) has discovered 1750 acetylated proteins in
a human leukemia cell line, but only 240 proteins were overlapping
in these two independent data sets. Nerve cells, which possess
particularly unique morphologies and specialized biological func-
tions, may display signiﬁcantly different acetylome proﬁles. OL cells
are a cell line derived from fetal human oligodendrocytes, which are
a major cellular component of the brain white matter that play a
pivotal role in maintaining neurological function. OL cells are targets
of several neurotropic NNS RNA viruses, including canine distemper
virus (Muller et al., 1995), measles virus (Baczko et al., 1988), and BDV
(Ibrahim et al., 2002; Zhai et al., 2013). Although neurons are the
primary targets of BDV, astroglia and oligodendroglia can be infected
by BDV as well (Carbone et al., 1993). As our previous study and
others have shown, various cell types react differently to different
BDV viral strains (Li et al., 2013; Poenisch et al., 2009; Williams et al.,
2008; Wu et al., 2013). Moreover, in virus-host interactions, several
speciﬁc acetylation sites have been demonstrated to play pivotal
roles (Huo et al., 2011; Lammers et al., 2010; Oussaief et al., 2009).
We could recently show that infection of human oligodendroglial
(OL) cells with a natural human BDV strain (Hu-H1) decreased the
acetylation levels in 50% of Kac sites in core histone tails lowering
host gene expression levels (Liu et al., 2014a, 2014b).
In this study, we largely extended our approach to compara-
tively proﬁle the entire acetylome of BDV Hu-H1-infected and
matched non-infected human OL cells, as Kac involves in a broad
range of cytoplasmic functions (Choudhary et al., 2009). We
thereby as well applied a stable isotope labeling with amino acids
in cell culture (SILAC)-based quantitative proteomic approach
combined with bioinformatic analysis.
Results
BDV infection of OL cells
Successful BDV infection of OL cells could be conﬁrmed by RT-PCR
and immunoﬂuorescence assays detecting p24 and p40 RNA and
protein levels (de la Torre,1994). Rapid spread of the virus was observed
in tissue culture; 100% of the cells were infected 14 days post-infection,
while 100% of control cells were remained uninfected (data not shown).
Quantiﬁcation of the Kac acetylome
We applied SILAC labeling-based proteomics to comparatively
quantify Kac changes in response to BDV infection. A scheme of the
experimental workﬂow is provided in Fig. 1. We detected a total of 827
non-redundant sites (795 in non-histone proteins and 32 in histones),
of which 791 were quantiﬁable. The detected Kac sites were present in
538 proteins, of which 473 were quantiﬁable (Table 1). The average
mass error for acetylated peptides was 0.1 ppm with a standard
deviation of only 1 ppm. Among the 791 quantiﬁable sites, 25% (194
Kac sites) displayed a greater than or equal to 1.5-fold differential
expression. The vast majority of this differentially expressed quarter
showed an increased acetylation in response to BDV infection (171;
88%), whereas only 23 Kac sites displayed a decrease.
Bioinformatic analysis
We applied the comprehensive protein-protein interaction net-
work database Search Tool for the Retrieval of Interacting Genes
(STRING) combined with the complex detection algorithm MCODE.
We could detect two enriched protein-protein interaction networks
in our dataset, namely the ribosomal protein network (po10–30) and
proteasome protein network (po10-6) (Table 2, Fig. 2). To improve
the reliability of protein-protein interaction we thereby applied a
conﬁdence score of greater than or equal to 0.7 (high conﬁdence)
To examine the nature of the acetylome in response to BDV
infection, we divided the acetylation dataset into four quantiles
based on the cumulative distribution of OL/OL-BDV (L/H) Log2 SILAC
ratios (Q1, less than 15%; Q2, 15%-30%; Q3, 70%-85%; Q4, more than
85%) and one quantile (30%-70%) for the sites without differential
expression towards BDV infection. An enrichment analysis was
separately performed in each quantile for diverse categories, and
the overrepresented annotations were clustered through one-way
hierarchical clustering allowing comparative analysis. To elucidate
the cellular functions of acetylated proteins regulated by BDV
infection, we tested the dataset for enrichment in three Gene
Ontology (GO) categories: biological process, molecular function,
and cellular compartmentalization (Fig. 3A-C). To reveal the dysre-
gulated domain structures, we performed Interpro domain enrich-
ment analysis on the four SILAC ratio quantiles (Fig. 4A). To identify
dysregulated cellular pathways, a pathway clustering analysis of the
BDV-response Lys acetylome was performed using the Kyoto
Encyclopedia of Genes and Genomes (KEGG) (Fig. 4B). Using a
manually-curated CORUM database, we performed an enrichment
analysis on protein complexes, and then used k-means clustering to
identify the speciﬁc sub-groups that are most impacted by BDV
infection (Fig. 4C). The results are summarized in Table 3.
Butanoate, fatty acid, and amino acid metabolism
Acetylation has been shown to play a key role in regulating
cellular energy metabolism (Zhao et al., 2010). We could identify
signiﬁcant alterations in energy-linked host biological pathways
related to butanoate metabolism and fatty acid elongation/degrada-
tion upon BDV infection, as indicated in the high SILAC L/H ratio
quantile through KEGG analysis. Butanoate refers to the metabolism
of several short-chain fatty acids which are used to synthesize
ketone bodies, short-chain lipids, and precursors of glycolysis and
the tricarboxylic acid cycle (TCA cycle). Here, we found increased
acetylation of speciﬁc Kac sites of six proteins involved in butanoate
metabolism (i.e., K174 on ACAT1, K118 on ECHS1, K317 on HADH,
K48 on HMGCL, K463 on OXCT1 and K101 on PDHA1) in response to
BDV infection. Furthermore, Interpro domain enrichment analysis
showed that the high SILAC L/H ratio quantile was enriched for
protein domains involved in fatty acid metabolic activities (i.e., 3-
hydroxyacyl-CoA dehydrogenase, thiolase, crontonase).
In addition, the metabolism of several amino acids (i.e., beta-
alanine, tryptophan, lysine, valine, leucine, and isoleucine) was also
signiﬁcantly enriched in the high SILAC L/H ratio quantile, corre-
sponding to elevated alanine, valine, and isoleucine levels pre-
viously reported in our metabonomic study (Huang et al., 2012).
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The acetylation of KATs regulated by BDV infection
In response to BDV infection, we found several KATs with one
or more altered Kac sites (i.e., CREBBP, ACAT1, DLAT, EP300,
MEAF6, MYST2, MYST4, NAA30, NAA50, and NAT10). In particular,
the acetylation levels of K174 on ACAT1, K1042 on MYST4, K466 on
DLAT, K199 on MYST2, and K74 on MEAF6 were found to be
signiﬁcantly increased (Z1.5 fold-change), while K1044 on MYST4
as well as K1861, K1836, and K1839 on CREBBP were found to be
signiﬁcantly decreased (r1.5 fold-change).
Discussion
The goal of this study was to analyze the impact of an ancient
neurotropic RNA virus (Liu et al., 2014a, 2014b) with long co-
evolution in its primate ancestor hosts up to humans (Horie et al.,
2010) on an ancient and ubiquitous PTM which regulates a large
army of cytoplasmic and nuclear cell functions in response to any
kind of changes (Beltrao et al., 2013; Choudhary et al., 2009). After
our previous work had established that acetylation levels in Kac
sites of core histone tails were lowered in 50% of sites upon human
BDV infection (Liu et al., 2014a, 2014b), this study focused on the
effects of this natural virus strain (BDV Hu-H1 (Bode et al., 1996))
on the entire acetylome of human oligodendroglial (OL) cells
through a SILAC-based quantitative proteomic approach. To date,
several studies have addressed the effects of host or viral protein
acetylation upon virus-host interaction or virus pathogenesis. For
example, acetylation of Smad3 contributes to Epstein-Barr virus
(EBV) reactivation (Oussaief et al., 2009), acetylation of cyclophilin
A affects human immunodeﬁciency virus (HIV)-1 infection by
stabilizing cis rather than trans forms of the HIV-1 capsid
(Lammers et al., 2010), and Lys-28 acetylation of Tat is essential
for HIV-1 transcription and replication by modulating the afﬁnity
and stability of HIV-1 Tat-CycT1-TAR complexes (D’Orso and
Frankel, 2009). However, to our knowledge, this study is the ﬁrst
to systematically describe and analyze Lys-acetylated proteins in
response to BDV infection covering the entire acetylome of OL cell.
The strength of our study lies in that a basic ancient post-
translational modiﬁcation (PTM) like Kac could be related to BDV
persistence. What we could not include and leave to future
studies, however, were functional data directly elucidating the
biological consequences in the acetylome of infected OL cells.
Despite of this weakness of the study, we think that the observed
shift in the acetylome of BDV-infected cells allows conclusions
about which direction cell metabolism are forced to go upon
infection. The discussion below will consider potential implica-
tions thoroughly. It will furthermore offer hypotheses, which are
still speculative but might stimulate new avenues in research.
In general, our bioinformatically analyzed results revealed that
BDV infection dysregulates the Kac states of diverse cellular
pathways, preferentially alters the acetylation of proteins involved
in butanoate, fatty acid, and amino acid metabolism as well as
membrane-associated proteins and transmembrane transporter
activity, and affects the acetylation of several KATs.
In particular, these aspects are discussed in further detail below.
Butanoate, fatty acid, and amino acid metabolism
Acetylation plays a key role in regulating cellular energy meta-
bolism (Zhao et al., 2010). We could show through KEGG as well as
Interpro domain enrichment analysis that energy-related host
biological pathways, particularly involving butanoate and fatty acid
metabolism, were signiﬁcantly increased upon BDV infection.
Viral replication requires energy derived from the metabolic
network of the host cell. This is particularly known for large DNA
viruses like herpes viruses which are able to actively redirect their
host cells' energy metabolism and signiﬁcantly perturb glycolysis,
TCA cycle, and pentose phosphate pathway intermediates (Vastag
et al., 2011). In terms of BDV which is less than 10 times the size of
herpes viruses, the most signiﬁcantly altered pathways were those
linked to energy metabolism, as shown in previous studies of our
group (Huang et al., 2012; Liu et al., 2014a, 2014b). In line with
these ﬁndings, we could demonstrate here that acetylation levels
of speciﬁc Kac sites of six proteins involved in butanoate metabo-
lism (i.e., K174 on ACAT1, K118 on ECHS1, K317 on HADH, K48 on
HMGCL, K463 on OXCT1 and K101 on PDHA1) were increased in
response to BDV infection. This suggests a shift of the acetylome
towards higher energy levels upon BDV persistence.
In addition, the metabolism of several amino acids (i.e., beta-
alanine, tryptophan, lysine, valine, leucine, and isoleucine) was also
signiﬁcantly enriched in the high SILAC L/H ratio quantile, supporting
previous metabonomic data (Huang et al., 2012). BDV affects amino
acid metabolism through an acetylation-based mechanism. Notably,
beta-alanine is a small molecule inhibitory neurotransmitter and has
been shown to be neuro-protective and to reduce inﬂammation and
oxidative stress in the central nervous system (Gibbons et al., 2014;
Tiedje et al., 2010). Valine and isoleucine are branched-chain amino
acids suggested to affect monoamine neurotransmitter levels in rats
upon valproate medication (Maciejak et al., 2014).
Membrane-associated proteins and transmembrane transporter
activity
BDV enters cells by plasma membrane fusion, replicates and
transcribes itself in the nucleus, and then self-replicates through
nucleocytoplasmic trafﬁcking of BDV macromolecules (Gonzalez-
Dunia et al., 1998; Honda and Tomonaga, 2013). Here, the GO
analysis of molecular function suggested that BDV infection is
likely to impact on membrane/transporter proteins required for
shuttling of viral components. As mitochondrial F1F0ATP
synthase – a proton transporter which localizes to the inner
mitochondrial membrane (Strauss et al., 2008) – was enriched in
the SILAC L/H ratio quantile with signiﬁcantly increased acetyla-
tion levels, BDV may alter transmembrane transporter activity in
OL cells through acetylation of membrane-associated proteins.
KAT acetylation
Lysine acetyltransferases (KATs) catalyze the transfer of acetyl
groups from acetyl-CoA to epsilon amino groups. Autoacetylation of
KAT subunits is a well-established phenomenon with some KATs
having more than 40 acetylated subunits (Choudhary et al., 2009;
Lee and Workman, 2007). The current study found 10 KATs with
one or more altered Kac sites in response to BDV infection, some of
which, however, displayed opposite acetylation levels, for example
on MYST4 and CREBBP. It is a new ﬁnding without many previous
studies. A reasonable explanatory hypothesis may be that this may
be part of a tailored activity regulation comparable to what is
known for multiple PTMs on the same protein molecule which
together determine a functional outcome (Beltrao et al., 2013).
In our recent study on histone lysine acetylation, we had found
a signiﬁcantly altered expression of several histone acetyltrans-
ferases (HATs) and histone deacetylases (HDACs) in BDV infected
OL cells. We could also conﬁrm two HATs (GCN5 and PCAF) and
eight HDACs (SIRT1, SIRT2, HDACs 1, 2, 3, 4, 5, and 7) by Western
blotting. GCN5 and PCAF were found to be signiﬁcantly down-
regulated, and SIRT1, SIRT2, HDAC4 and HDAC7 to be signiﬁcantly
upregulated in OL/BDV cells compared to control cells (Liu et al.,
2014a, 2014b). Interestingly, all above HATs and HDACs are not
acetylated proteins in current data of this study.
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Our present ﬁnding of predominantly increased acetylation of
those Kac sites differentially expressed by BDV infection could be
of particular interest in future studies addressing the intense
cross-talk to another ancient PTM, namely phosphorylation
(Beltrao et al., 2013; Mischerikow and Heck, 2011) which largely
regulates the functional state of the cell. Both PTMs have been
shown to be also very common in prokaryotes like Mycoplasma
pneumonia, and are often observed at interaction interfaces and in
multifunctional proteins (van Noort et al., 2012). BDV P-protein
(p24) is post-translationally phosphorylated by protein kinase C
(PKC) at two serine residues (S26 and S28) which represent the
major phosphorylation site (Schwemmle et al., 1997). This site is
also part of the conformational epitope on P-protein which is
recognized by a monoclonal antibody capable to detect active P-
protein (Bode, 2008). N/P-protein–antibody complexes (CICs) are
likely more common in infected people's plasma than antibodies
alone (Bode and Ludwig, 2003), and were recently used to screen
the infection risk of health care personnel (Liu et al., 2015). In this
in vitro study we could show that proteins in the high SILAC L/H
ratio quantile (Q4) are enriched for phosphate-associated meta-
bolic processes. Although direct functional data are lacking, we
like to make our point that this ﬁnding may indirectly argue in
favor of an intertwining network of acetylation and phosphoryla-
tion as the major target of BDV interference, worth it to be
addressed in future studies. The key role of P-protein in BDV
neuropathogenesis had been highlighted by Kamitani et al. (2003),
who could demonstrate through a transgenic mice model that the
presence of P-protein in the brain alone is capable to induce
behavioral and neurological abnormalities. We therefore like to
bring forward the idea of an interacting regulatory activity of
phosphorylation and acetylation as part of the key pathogenesis
mechanism which may initiate a new line of BDV future research.
Conclusions
This study aimed to ﬁgure out whether and to which extent
persistent infection of an ancient neurotropic RNA virus (BDV)
manipulates ancient post-translational modiﬁcations (PTMs) of its
host cell, by using a SILAC-based quantitative proteomic approach
coupled with bioinformatic analysis. The strength of our study is
that this is the ﬁrst analysis of the entire host acetylome of OL cells
after persistent infection with a natural human strain of BDV. We
found that a quarter of lysine acetylation (Kac) sites were differ-
entially expressed, the majority of these sites displaying increased
acetylation. Upon persistent BDV infection, preferentially the
acetylation levels of proteins involved in butanoate, fatty acid,
and amino acid metabolism, as well as membrane-associated
proteins and transmembrane transporter activity were altered,
affecting also the acetylation of several KATs. The weakness of our
study lies in that our data are mainly descriptive, and yet no direct
functional data are included. However, despite these ﬂaws, the
direction of changes as compared to uninfected cells, as indicated
by the respective acetylome shift, does support the conclusion that
BDV persistence manipulates cell metabolism towards higher
energy and transporter levels. This remarkable shift leads us to
hypothesize that BDV might maintain persistence through manip-
ulating an evolutionary early PTM function. Based on the ﬁnding of
enriched phosphate-associated metabolic processes, we further
like to bring forward the idea that acetylation and phosphorylation
networks could be intertwined major targets of BDV interference,
facilitating energy-demanding processes like shuttling of BDV
proteins to and from nuclear replication sites. Future studies
should investigate whether these hypotheses could be corrobo-
rated and the postulated link to the crucial role of P-protein in BDV
neuropathogenesis gets functionally supported.
Material and methods
History of viral strain
The human strain BDV Hu-H1 isolated in Germany was used
throughout the study (Bode et al., 1996). This strain could be
isolated from freshly prepared white blood cells of a female bipolar
I disorder patient in Germany, who needed urgent admission to
hospital during a severe depressive episode. Isolation was achieved
by co-cultivating the patient's PBMC with human oligodendroglia
(OL) cells, after at least 10–12 blind passages without exhibiting
viral growth. Isolating Hu-H1 and two other human strains was part
of a huge experiment including coded, randomly selected PBMCs of
healthy donors as well as of psychiatric patients, altogether adding
up to more than 1000 passages. Finally, only few (2.5%) turned out
to grow the virus continuously from passage 12 and higher (Bode et
al., 1996). Hu-H1 and the other two isolates were originating from
PBMC samples testing positive for BDV RNA and protein. Original
RNAs as well as the RNAs of the isolates were sequenced by
molecular biologists at Scripps (USA, CA) who had never handled
the BDV reference strain V (de la Torre et al., 1996).
Corresponding RNAs (of PBMC and isolate) displayed identical
nucleotide sequences, sufﬁciently proving the authenticity of the
human isolates (de la Torre et al., 1996). Moreover, the isolates
displayed few but meaningful point mutations differentiating them
from each other and from laboratory strain V and a second lab
strain (He/80). In vivo, this and the other two strains displayed
differing pathogenicity, namely inducing behavioral changes in
rabbits but no deadly disease as compared to str. V (Bode et al.,
1996); in vitro, Hu-H1 inhibited proliferation and supported apop-
tosis, whereas lab. Strain V did quite the opposite (Li et al., 2013).
Despite the above evidence, the authenticity of the human strains
has been doubted arguing with the high level of sequence con-
servation of BDVgenomes displaying less than 5% of divergence at
the nucleotide level and less than 1% at the protein level. However,
phylogenetic analyses claiming to support contamination are based
on the comparison of very short gene stretches instead of complete
genome sequences which is prone to misinterpretation, especially
in case of a highly conserved virus (Bode, 2008).
According to its history and our own experience, the human strain
Hu-H1 is an authentic own BDV strain displaying a different physio-
logical proﬁle in host cells compared to the highly adapted laboratory
strain V originating from a horse with Borna disease (Li et al., 2013).
This context argues clearly in favor of using a wild-type strain.
Cell lines and viral strain propagation
Virus stock of the human strain BDV Hu-H1 (77 passages in
human OL cells) and the uninfected OL cell line derived from human
fetal oligodendrocytes (112 passages) were kindly supplied by
Professor Hanns Ludwig (Free University of Berlin, Berlin, Germany).
A comprehensive description of the strain and standard cell culture
conditions was given previously (Liu et al., 2014a, 2014b).
Viral infection
Viral infection and the preparation of viral stock solution
followed the previous protocol (Liu et al., 2014a, 2014b). In brief,
OL cells were sub-cultured in one 10-cm dish and washed twice
with serum-free DMEM prior to infection with BDV Hu-H1 stock
solution at a multiplicity of infection (MOI) of 1.0 (800 μl) (Huang
et al., 2012). Cells were then stored in a humidiﬁed incubator (5%
CO2, 37 1C) for two hours with gentle shaking for 15 min. Excess
virus was removed by washing with 5 ml of serum-free DMEM
before bathing the cells in 10 ml of culture medium (10% FBS in
DMEM). Thereafter, these cells were passaged 30 times until all
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Table 1
List of quantiﬁable and non-quantiﬁable differential acetylated proteins by SILAC.
No. Protein IPI no. Homo-protein name Modiﬁed position Modiﬁed sequence L/H ratio
Quantiﬁable
1 IPI01009314 CREBBP 1836 _VVQHTK(ac)GCK(ac)R_ 0.15
2 IPI01009314 CREBBP 1839 _VVQHTK(ac)GCK(ac)R_ 0.15
3 IPI00514806 S100A2 26 _YSCQEGDK(ac)FK_ 0.16
4 IPI01009314 CREBBP 1861 _QLIALCCYHAK(ac)HCQENK_ 0.25
5 IPI00396341 C2orf67 848 _WSLWEQSK(ac)WHR_ 0.40
6 IPI00099433 MYST4 1044 _VQSK(ac)NK(ac)YLHSPESR_ 0.43
7 IPI00021396 KDR 826 _LPYDASK(ac)WEFPR_ 0.50
8 IPI00983509 STMN1 129 _ALEENNNFSK(ac)MAEEK_ 0.50
9 IPI00216134 TPM3 152 _EAK(ac)HIAEDADR_ 0.51
10 IPI00219219 LGALS1 108 _LPDGYEFK(ac)FPNR_ 0.52
11 IPI00083708 BAT2L2 49 _HGLQSLGK(ac)VGISR_ 0.53
12 IPI00030275 TRAP1 629 _MQQLAK(ac)TQEER_ 0.55
13 IPI00298994 TLN1 1917 _PAAVAAENEEIGSHIK(ac)HR_ 0.57
14 IPI00916332 MLL3 2809 _TLVLSDK(ac)HSPQK_ 0.59
15 IPI00479997 STMN1 80 _EHEK(ac)EVLQK_ 0.60
16 IPI00221226 ANXA6 9 _PAQGAK(ac)YR_ 0.60
17 IPI00795671 RAN 23 _LVLVGDGGTGK(ac)TTFVK_ 0.61
18 IPI00479997 STMN1 128 _DK(ac)HIEEVRK_ 0.62
19 IPI00479997 STMN1 70 _SHEAEVLK(ac)QLAEK_ 0.63
20 IPI00026781 FASN 673 _EGVFAK(ac)EVR_ 0.64
21 IPI00221088 RPS9 121 _LGLAK(ac)SIHHAR_ 0.65
22 IPI00026781 FASN 436 _TPEAVQK(ac)LLEQGLR_ 0.65
23 IPI00014513 YY1 315 _K(ac)HLHTHGPR_ 0.66
24 IPI00384471 BRD1 1008 _GK(ac)PALVR_ 0.67
25 IPI00216654 NOLC1 515 _VAGGAAPSK(ac)PASAK_ 0.68
26 IPI00307223 IL1B 59 _ISDHHYSK(ac)GFR_ 0.68
27 IPI00479997 STMN1 119 _EAQMAAK(ac)LER_ 0.69
28 IPI00099433 MYST4 393 _VCTTPSSGHAASGK(ac)DSSSR_ 0.69
29 IPI00218918 ANXA1 250 _HDMNK(ac)VLDLELK_ 0.70
30 IPI00922055 DBI 138 _AYINK(ac)VEELK_ 0.70
31 IPI00513698 TPM2 152 _EAK(ac)HIAEDSDR_ 0.70
32 IPI00289159 GLS 164 _FITALK(ac)STGLR_ 0.70
33 IPI00019502 MYH9 1404 _HEEK(ac)VAAYDK_ 0.71
34 IPI00982850 65 _TGK(ac)TVSYLGLE_ 0.71
35 IPI00028091 ACTR3 251 _YDTDGSK(ac)WIK_ 0.71
36 IPI00019502 MYH9 1024 _NK(ac)HEAMITDLEER_ 0.71
37 IPI00018146 YWHAQ 80 _LQLIK(ac)DYR_ 0.72
38 IPI00418471 VIM 445 _TLLIK(ac)TVETR_ 0.72
39 IPI00418471 VIM 292 _NLQEAEEWYK(ac)SK_ 0.73
40 IPI00002745 CTSZ 166 _DQECDK(ac)FNQCGTCNEFK_ 0.73
41 IPI01009314 CREBBP 1741 _FVYTCNECK(ac)HHVETR_ 0.73
42 IPI00414676 HSP90AB1 559 _AK(ac)FENLCK_ 0.73
43 IPI00294495 UFC1 122 _ICLTDHFK(ac)PLWAR_ 0.73
44 IPI00026781 FASN 1847 _YMAQGK(ac)HIGK_ 0.74
45 IPI00478410 ATP5C1 154 _THSDQFLVAFK(ac)EVGR_ 0.74
46 IPI00026202 RPL18A 41 _IFAPNHVVAK(ac)SR_ 0.74
47 IPI00301263 CAD 2036 _HPQPGAVELAAK(ac)HCR_ 0.75
48 IPI00784090 CCT8 20 _EGAK(ac)HFSGLEEAVYR_ 0.76
49 IPI00218918 ANXA1 245 _YSK(ac)HDMNK_ 0.76
50 IPI00910513 GSPT1 246 _TLEK(ac)YER_ 0.76
51 IPI00019927 PSMD7 204 _GLNSK(ac)LLDIR_ 0.76
52 IPI00023640 PDCD5 33 _HGDPGDAAQQEAK(ac)HR_ 0.76
53 IPI00555744 RPL14 85 _ADINTK(ac)WAATR_ 0.77
54 IPI00479186 PKM2 270 _IISK(ac)IENHEGVR_ 0.77
55 IPI00418471 VIM 294 _SK(ac)FADLSEAANR_ 0.77
56 IPI00641948 FUBP1 230 _GGETIK(ac)QLQER_ 0.77
57 IPI00023640 PDCD5 105 _VSQQTEK(ac)TTTVK_ 0.77
58 IPI00418471 VIM 139 _ILLAELEQLK(ac)GQGK_ 0.77
59 IPI00032406 DNAJA2 158 _SGAVQK(ac)CSACR_ 0.78
60 IPI00922055 DBI 116 _AK(ac)WDAWNELK_ 0.78
61 IPI00418471 VIM 235 _KVESLQEEIAFLK(ac)K_ 0.78
62 IPI00019502 MYH9 1212 _VK(ac)ANLEK_ 0.78
63 IPI00020985 EP300 1560 _NK(ac)SSLSR_ 0.78
64 IPI00456620 BRPF1 580 _DSEDK(ac)NWALK_ 0.79
65 IPI00023640 PDCD5 20 _LAELQAK(ac)HGDPGDAAQQEAK_ 0.80
66 IPI00984795 DSTN 116 _MLPDK(ac)DCR_ 0.80
67 IPI00219420 SMC3 105 _VIGAK(ac)K(ac)DQYFLDK_ 0.80
68 IPI00414676 HSP90AB1 624 _K(ac)HLEINPDHPIVETLR_ 0.80
69 IPI00418169 ANXA2 251 _YK(ac)SYSPYDMLESIR_ 0.80
70 IPI00219077 LTA4H 20 _TK(ac)HLHLR_ 0.80
71 IPI00549725 PGAM1 157 _YADLTEDQLPSCESLK(ac)DTIAR_ 0.80
72 IPI00291510 IMPDH2 257 _QLLCGAAIGTHEDDK(ac)YR_ 0.80
73 IPI00419249 PSMA3 183 _LQMK(ac)EMTCR_ 0.80
74 IPI00019502 MYH9 1648 _LQAQMK(ac)DCMR_ 0.80
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75 IPI00419373 HNRNPA3 187 _IVVQK(ac)YHTINGHNCEVK_ 0.81
76 IPI00984795 DSTN 182 _HELQANCYEEVK(ac)DR_ 0.81
77 IPI00977661 37 _ETAQAIK(ac)GMHIR_ 0.81
78 IPI00789101 PTGES3 69 _HLNEIDLFHCIDPNDSK(ac)HK_ 0.81
79 IPI00470498 SERBP1 314 _SK(ac)SEEAHAEDSVMDHHFR_ 0.81
80 IPI00018251 NCOA2 785 _LIAMK(ac)TEK_ 0.81
81 IPI00382470 HSP90AA1 698 _IMK(ac)DILEK_ 0.82
82 IPI00028091 ACTR3 244 _EFNK(ac)YDTDGSK_ 0.82
83 IPI00218918 ANXA1 287 _LHQAMK(ac)GVGTR_ 0.82
84 IPI00465248 ENO1 406 _LAK(ac)YNQLLR_ 0.82
85 IPI00465248 ENO1 262 _YDLDFK(ac)SPDDPSR_ 0.82
86 IPI00414676 HSP90AB1 568 _LMK(ac)EILDK_ 0.82
87 IPI00010157 MAT2A 88 _EAVK(ac)HIGYDDSSK_ 0.82
88 IPI00246975 GSTM3 87 _K(ac)HNMCGETEEEK_ 0.83
89 IPI00024175 PSMA7 52 _SVAK(ac)LQDER_ 0.83
90 IPI00018352 UCHL1 78 _GQEVSPK(ac)VYFMK_ 0.83
91 IPI00015911 DLD 122 _LNLDK(ac)MMEQK_ 0.83
92 IPI00977912 58 _HQPHK(ac)VTQYK_ 0.83
93 IPI00171903 HNRNPM 698 _GCGVVK(ac)FESPEVAER_ 0.83
94 IPI00382470 HSP90AA1 600 _YYTSASGDEMVSLK(ac)DYCTR_ 0.83
95 IPI00930688 TUBA1B 401 _FDLMYAK(ac)R_ 0.83
96 IPI00296337 PRKDC 3840 _APPCEYK(ac)DWLTK_ 0.84
97 IPI00926010 267 _LISNGYK(ac)DEWLQQQQR_ 0.84
98 IPI00000684 UAP1 63 _AIEGFNQSSHQK(ac)NVDAR_ 0.84
99 IPI00848161 BAT1 191 _HIK(ac)HFILDECDK_ 0.84
100 IPI00005154 SSRP1 319 _VMK(ac)ALVNR_ 0.84
101 IPI00456969 DYNC1H1 4283 _SFDSEFK(ac)LACK_ 0.84
102 IPI00179330 RPS27A 104 _LAVLK(ac)YYK_ 0.84
103 IPI00947127 LDHA 347 _K(ac)SADTLWGIQK_ 0.84
104 IPI00328389 NPM2 202 _SPVKKAK(ac)ATAR_ 0.84
105 IPI00221035 BTF3 67 _IGGK(ac)GTAR_ 0.84
106 IPI00216654 NOLC1 406 _NSSNKPAVTTK(ac)SPAVK_ 0.84
107 IPI00927658 85 _TK(ac)HMLPSGFR_ 0.84
108 IPI00419585 PPIA 82 _SIYGEK(ac)FEDENFILK_ 0.84
109 IPI00303318 FAM49B 308 _YTTK(ac)HLNDETTSK_ 0.85
110 IPI01020905 166 _APGTPHSHTK(ac)PYVR_ 0.85
111 IPI00069817 BAZ1B 432 _K(ac)GLK(ac)TPK(ac)TK_ 0.85
112 IPI00069817 BAZ1B 429 _K(ac)GLK(ac)TPK(ac)TK_ 0.85
113 IPI00069817 BAZ1B 426 _K(ac)GLK(ac)TPK(ac)TK_ 0.85
114 IPI00978180 31 _KDVHMPK(ac)HPELADK_ 0.85
115 IPI00000494 RPL5 48 _YNTPK(ac)YR_ 0.86
116 IPI00014213 LARS2 236 _VEQK(ac)YLR_ 0.86
117 IPI00984795 DSTN 57 _VFNDMK(ac)VR_ 0.86
118 IPI00019502 MYH9 1099 _VEEEAAQK(ac)NMALK_ 0.86
119 IPI00465361 RPL13 11 _NGMVLK(ac)PHFHK_ 0.86
120 IPI00013808 ACTN4 455 _K(ac)HEAFESDLAAHQDR_ 0.86
121 IPI00382470 HSP90AA1 206 _ELHINLIPNK(ac)QDR_ 0.86
122 IPI00930688 TUBA1B 60 _TIGGGDDSFNTFFSETGAGK(ac)HVPR_ 0.86
123 IPI00419585 PPIA 49 _GFGYK(ac)GSCFHR_ 0.86
124 IPI00419585 PPIA 125 _TEWLDGK(ac)HVVFGK_ 0.86
125 IPI00217030 RPS4X 16 _VAAPK(ac)HWMLDK_ 0.87
126 IPI00008054 BRPF3 1039 _GK(ac)PALSR_ 0.87
127 IPI00219420 SMC3 106 _VIGAK(ac)K(ac)DQYFLDK_ 0.87
128 IPI00438229 TRIM28 213 _TVYCNVHK(ac)HEPLVLFCESCDTLTCR_ 0.87
129 IPI00465248 ENO1 126 _AGAVEK(ac)GVPLYR_ 0.87
130 IPI00006451 NSF 401 _MEIGLPDEK(ac)GR_ 0.87
131 IPI00220503 DCTN2 300 _VNEIAK(ac)HK_ 0.87
132 IPI00916332 MLL3 827 _IGMGK(ac)PAITK_ 0.87
133 IPI00477842 SRSF8 36 _VFEK(ac)YGR_ 0.87
134 IPI00867533 RPL6 192 _THQK(ac)FVIATSTK_ 0.87
135 IPI00966503 13 _NK(ac)AVQSVR_ 0.88
136 IPI00922055 DBI 80 _TK(ac)PSDEEMLFIYGHYK_ 0.88
137 IPI00828098 NET57 2499 _LVK(ac)VHGGTTADM(ox)IYSRVR_ 0.88
138 IPI00216247 PSMD4 98 _VAHLALK(ac)HR_ 0.88
139 IPI00867533 RPL6 239 _EK(ac)YEITEQR_ 0.88
140 IPI00003918 RPL4 364 _AAAAAAALQAK(ac)SDEK_ 0.88
141 IPI00384471 BRD1 23 _HPSSPCSVK(ac)HSPTR_ 0.88
142 IPI00604620 NCL 444 _TEADAEK(ac)TFEEK_ 0.88
143 IPI00013146 MRPS22 248 _VHHK(ac)TYEDIDKR_ 0.88
144 IPI00382470 HSP90AA1 635 _K(ac)HGLEVIYMIEPIDEYCVQQLK_ 0.88
145 IPI00414676 HSP90AB1 286 _TK(ac)PIWTR_ 0.88
146 IPI00186290 EEF2 498 _VMK(ac)FSVSPVVR_ 0.88
147 IPI00456429 UBA52 88 _QLAQK(ac)YNCDK_ 0.88
148 IPI00291467 SLC25A6 105 _QIFLGGVDK(ac)HTQFWR_ 0.88
149 IPI00436632 NIPBL 770 _DSGK(ac)PSTEK_ 0.88
150 IPI00215965 HNRNPA1 350 _SSGPYGGGGQYFAK(ac)PR_ 0.89
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151 IPI00555744 RPL14 71 _FPHSAHQK(ac)YVR_ 0.89
152 IPI00000816 YWHAE 106 _LICCDILDVLDK(ac)HLIPAANTGESK_ 0.89
153 IPI00220031 PXN 554 _GSLCSGCQK(ac)PITGR_ 0.89
154 IPI00297779 CCT2 176 _LLTHHK(ac)DHFTK_ 0.89
155 IPI00221089 RPS13 39 _EQIYK(ac)LAK_ 0.89
156 IPI00952583 MDH1 121 _DLLK(ac)ANVK_ 0.89
157 IPI00853161 78 _YMVK(ac)SCGK_ 0.89
158 IPI00015897 CHORDC1 89 _ELCELK(ac)PK_ 0.89
159 IPI00795671 RAN 151 _AK(ac)SIVFHR_ 0.89
160 IPI00473014 DSTN 19 _IFYDMK(ac)VR_ 0.89
161 IPI00419880 RPS3A 46 _NIGK(ac)TLVTR_ 0.89
162 IPI00003865 HSPA8 512 _LSK(ac)EDIER_ 0.89
163 IPI00479191 NCL 185 _YIEIFK(ac)SSR_ 0.89
164 IPI00382470 HSP90AA1 331 _K(ac)HSQFIGYPITLFVEK_ 0.89
165 IPI00419585 PPIA 31 _VPK(ac)TAENFR_ 0.89
166 IPI00456969 DYNC1H1 1125 _YDSWHK(ac)EVLSK_ 0.90
167 IPI00304596 NONO 198 _GIVEFSGK(ac)PAAR_ 0.90
168 IPI00152906 HIST1H2BD 117 _HAVSEGTK(ac)AVTK_ 0.90
169 IPI00027230 HSP90B1 97 _NK(ac)EIFLR_ 0.90
170 IPI00419585 PPIA 131 _HVVFGK(ac)VK_ 0.90
171 IPI00983620 PPIA 131 _HVVFGK(ac)VK_ 0.90
172 IPI00007423 ANP32B 28 _ELVLDNCK(ac)SNDGK_ 0.90
173 IPI00916600 SLC25A24 142 _VFDK(ac)DGNGYISAAELR_ 0.90
174 IPI00456969 DYNC1H1 371 _NTK(ac)YPIQR_ 0.90
175 IPI00947127 LDHA 261 _EVHK(ac)QVVESAYEVIK_ 0.90
176 IPI00794659 RPS20 75 _TPCGEGSK(ac)TWDR_ 0.90
177 IPI00942979 TKT 144 _YFDK(ac)ASYR_ 0.90
178 IPI00008274 CAP1 71 _EIGGDVQK(ac)HAEMVHTGLK_ 0.90
179 IPI00007752 TUBB2C 58 _INVYYNEATGGK(ac)YVPR_ 0.90
180 IPI00645948 HMGB1 30 _K(ac)HPDASVNFSEFSK_ 0.90
181 IPI00640703 XPO5 1160 _LIAGCIGK(ac)PLGEQFR_ 0.91
182 IPI00419585 PPIA 44 _ALSTGEK(ac)GFGYK_ 0.91
183 IPI00643351 346 _RRPENPK(ac)PQDGK_ 0.91
184 IPI00867533 RPL6 94 _VLATVTK(ac)PVGGDK_ 0.91
185 IPI00000643 BAG2 195 _LLEHSK(ac)GAGSK_ 0.91
186 IPI00376798 RPL11 154 _TGCIGAK(ac)HR_ 0.91
187 IPI00218319 TPM3 116 _EAK(ac)HIAEEADR_ 0.91
188 IPI00220403 HIST1H2BB 13 _K(ac)GSK(ac)K(ac)AITK_ 0.91
189 IPI00220403 HIST1H2BB 16 _K(ac)GSK(ac)K(ac)AITK_ 0.91
190 IPI00009771 LMNB2 520 _FTPK(ac)YILR_ 0.91
191 IPI00217030 RPS4X 120 _ITPEEAK(ac)YK_ 0.91
192 IPI00219156 RPL30 87 _TGVHHYSGNNIELGTACGK(ac)YYR_ 0.91
193 IPI00639841 PECI 92 _AK(ac)WDAWNALGSLPK_ 0.91
194 IPI00456620 BRPF1 1033 _GK(ac)PSFSR_ 0.91
195 IPI00009946 TOMM34 63 _AACHLK(ac)DGNCR_ 0.91
196 IPI01019113 ENSG00000224156 58 _ISVYYNEATGGK(ac)YVPR_ 0.92
197 IPI00554777 ASNS 440 _IPK(ac)NGIEK_ 0.92
198 IPI00216682 CNN3 23 _IASK(ac)YDHQAEEDLR_ 0.92
199 IPI00479743 POTEE 891 _ELPDYLM(ox)K(ac)ILTER_ 0.92
200 IPI00013415 RPS7 74 _SFQK(ac)IQVR_ 0.92
201 IPI00419880 RPS3A 182 _EVQTNDLK(ac)EVVNK_ 0.92
202 IPI00169383 PGK1 323 _K(ac)YAEAVTR_ 0.92
203 IPI00333541 FLNA 2607 _TPCEEILVK(ac)HVGSR_ 0.92
204 IPI00018146 YWHAQ 122 _MK(ac)GDYFR_ 0.92
205 IPI00914566 FDPS 123 _EVLEYNAIGGK(ac)YNR_ 0.92
206 IPI00299573 RPL7A 212 _TCTTVAFTQVNSEDK(ac)GALAK_ 0.92
207 IPI00165981 ZNFX1 1665 _LK(ac)ALLER_ 0.92
208 IPI00000494 RPL5 197 _K(ac)HIMGQNVADYMR_ 0.92
209 IPI00009104 RUVBL2 9 _(ac)ATVTATTK(ac)VPEIR_ 0.93
210 IPI00438229 TRIM28 188 _YTK(ac)DHTVR_ 0.93
211 IPI00418471 VIM 373 _LQDEIQNMK(ac)EEMAR_ 0.93
212 IPI00984795 DSTN 159 _MIYASSK(ac)DAIK_ 0.93
213 IPI00853161 74 _ICANK(ac)YMVK_ 0.93
214 IPI00479186 PKM2 115 _PVAVALDTK(ac)GPEIR_ 0.93
215 IPI00382470 HSP90AA1 611 _ENQK(ac)HIYYITGETK_ 0.93
216 IPI00012007 AHCY 426 _QAQYLGMSCDGPFK(ac)PDHYR_ 0.93
217 IPI00020955 AKR1D1 71 _EK(ac)IAEGKVR_ 0.93
218 IPI00294158 BLVRA 269 _LLGQFSEK(ac)ELAAEK_ 0.93
219 IPI00013174 COAA 112 _VIECDVVK(ac)DYAFVHMEK_ 0.94
220 IPI00382470 HSP90AA1 754 _K(ac)HLEINPDHSIIETLR_ 0.94
221 IPI00104050 THRAP3 697 _HGLAHDEMK(ac)SPR_ 0.94
222 IPI00186290 EEF2 445 _KEDLYLK(ac)PIQR_ 0.94
223 IPI00643722 ARID1A 1880 _K(ac)HVTTAEGTPGTTDQEGPPPDGPPEK_ 0.94
224 IPI00003918 RPL4 106 _MFAPTK(ac)TWR_ 0.94
225 IPI00216691 PFN1 105 _STGGAPTFNVTVTK(ac)TDK_ 0.94
226 IPI01009314 CREBBP 1657 _LYATMEK(ac)HK_ 0.94
X. Liu et al. / Virology 485 (2015) 58–78 65
Table 1 (continued )
No. Protein IPI no. Homo-protein name Modiﬁed position Modiﬁed sequence L/H ratio
227 IPI00795671 RAN 60 _GPIK(ac)FNVWDTAGQEK_ 0.94
228 IPI00453473 HIST1H4H 60 _GVLK(ac)VFLENVIR_ 0.94
229 IPI00219160 RPL34 43 _APK(ac)SACGVCPGR_ 0.94
230 IPI00795671 RAN 37 _HLTGEFEK(ac)K_ 0.94
231 IPI00171903 HNRNPM 134 _AAEVLNK(ac)HSLSGR_ 0.95
232 IPI00470528 RPL15 153 _RNPDTQWITK(ac)PVHK_ 0.95
233 IPI00549725 PGAM1 106 _AETAAK(ac)HGEAQVK_ 0.95
234 IPI00465248 ENO1 256 _SGK(ac)YDLDFK_ 0.95
235 IPI00418169 ANXA2 170 _EMYK(ac)TDLEK_ 0.95
236 IPI00647457 HLA-ABC 292 _YTCHVQHEGLPK(ac)PLTLR_ 0.95
237 IPI00000684 UAP1 152 _LQQVAEK(ac)YYGNK_ 0.95
238 IPI00879666 RANBP1 104 _TK(ac)FEECR_ 0.95
239 IPI00396378 HNRNPA2B1 173 _IVLQK(ac)YHTINGHNAEVR_ 0.95
240 IPI00465248 ENO1 228 _EGLELLK(ac)TAIGK_ 0.95
241 IPI00010153 RPL23 13 _GGSSGAK(ac)FR_ 0.95
242 IPI00418169 ANXA2 320 _SEVDMLK(ac)IR_ 0.95
243 IPI00027626 CCT6A 10 _TLNPK(ac)AEVAR_ 0.96
244 IPI00031517 MCM6 643 _MHCCDEVQPK(ac)HVK_ 0.96
245 IPI01013939 CTTN 272 _GFGGK(ac)YGVQK_ 0.96
246 IPI00910781 GPI 377 _YITK(ac)SGTR_ 0.96
247 IPI00100313 PCID2 437 _GYISHQHQK(ac)LVVSK_ 0.96
248 IPI00795671 RAN 116 _VTYK(ac)NVPNWHR_ 0.96
249 IPI00297779 CCT2 154 _EALLSSAVDHGSDEVK(ac)FR_ 0.96
250 IPI00815851 LRRIQ1 368 _K(ac)NIVKQER_ 0.96
251 IPI00002520 SHMT2 464 _TAK(ac)LQDFK_ 0.96
252 IPI00855833 PRR12 1223 _LEPLK(ac)PLK_ 0.96
253 IPI00418169 ANXA2 133 _TPAQYDASELK(ac)ASMK_ 0.96
254 IPI00719752 EIF3B 204 _LK(ac)NVIHK_ 0.96
255 IPI00003865 HSPA8 328 _LDK(ac)SQIHDIVLVGGSTR_ 0.96
256 IPI00382470 HSP90AA1 689 _TK(ac)FENLCK_ 0.96
257 IPI00550021 RPL3 229 _GYK(ac)GVTSR_ 0.96
258 IPI00018465 CCT7 287 _IHHSGAK(ac)VVLSK_ 0.96
259 IPI00647650 EIF3H 288 _QQQQK(ac)HQYQQR_ 0.96
260 IPI00895778 PAPD4 221 _LFLVGSSLNGFGTRSSDGDLCLVVK(ac)EEPVNQK_ 0.96
261 IPI00299573 RPL7A 245 _HWGGNVLGPK(ac)SVAR_ 0.96
262 IPI00218918 ANXA1 239 _VFQK(ac)YTK_ 0.97
263 IPI00456758 RPL27A 47 _INFDK(ac)YHPGYFGK_ 0.97
264 IPI00419585 PPIA 76 _HNGTGGK(ac)SIYGEK_ 0.97
265 IPI00000643 BAG2 111 _NPQQQESLK(ac)HATR_ 0.97
266 IPI00003865 HSPA8 71 _NQVAMNPTNTVFDAK(ac)R_ 0.97
267 IPI00604590 puf 179 _LVAMK(ac)FLR_ 0.97
268 IPI00418169 ANXA2 342 _SLYYYIQQDTK(ac)GDYQK_ 0.97
269 IPI00456758 RPL27A 59 _VGMK(ac)HYHLK_ 0.97
270 IPI00604590 puf 56 _FEQK(ac)GFR_ 0.97
271 IPI00218918 ANXA1 53 _GGPGSAVSPYPTFNPSSDVAALHK(ac)AIMVK_ 0.97
272 IPI00215965 HNRNPA1 166 _IVIQK(ac)YHTVNGHNCEVR_ 0.97
273 IPI00292135 LBR 601 _YGVAWEK(ac)YCQR_ 0.97
274 IPI00465248 ENO1 5 _(ac)SILK(ac)IHAR_ 0.98
275 IPI00647217 SKIV2L2 198 _ALSNQK(ac)YR_ 0.98
276 IPI00219526 PGM1 419 _DHWQK(ac)YGR_ 0.98
277 IPI00002902 NOL9 189 _K(ac)ELKREAR_ 0.98
278 IPI00418169 ANXA2 331 _YGK(ac)SLYYYIQQDTK_ 0.98
279 IPI00513791 DOCK7 1962 _AHGELHEQFK(ac)R_ 0.98
280 IPI00376005 EIF5A 98 _K(ac)YEDICPSTHNMDVPNIK_ 0.98
281 IPI01009314 CREBBP 1627 _TNK(ac)NK(ac)SSISR_ 0.98
282 IPI01009314 CREBBP 1625 _TNK(ac)NK(ac)SSISR_ 0.98
283 IPI00942979 TKT 59 _YK(ac)SQDPR_ 0.98
284 IPI00853161 198 _LIPDGCGVK(ac)YIPSR_ 0.98
285 IPI00221226 ANXA6 265 _AMK(ac)GLGTR_ 0.98
286 IPI00027463 S100A6 26 _EGDK(ac)HTLSK_ 0.98
287 IPI00455457 HIST2H3PS2 80 _EIAQEFK(ac)TDLR_ 0.99
288 IPI00000816 YWHAE 123 _VFYYK(ac)MK_ 0.99
289 IPI00027626 CCT6A 199 _HK(ac)SETDTSLIR_ 0.99
290 IPI01015529 77 _VECGPK(ac)YPEAPPSVR_ 0.99
291 IPI00015911 DLD 127 _MMEQK(ac)STAVK_ 0.99
292 IPI00220871 RPL37 31 _AYHLQK(ac)STCGK_ 0.99
293 IPI00418313 214 _HAK(ac)WFQAR_ 0.99
294 IPI00018352 UCHL1 195 _MPFPVNHGASSEDTLLK(ac)DAAK_ 0.99
295 IPI00796062 COX17 30 _KPLKPCCACPETK(ac)K_ 0.99
296 IPI00013808 ACTN4 417 _LDHLAEK(ac)FR_ 0.99
297 IPI00186290 EEF2 594 _ETVSEESNVLCLSK(ac)SPNK_ 1.00
298 IPI00396485 EEF1A1 44 _FEK(ac)EAAEMGK_ 1.00
299 IPI00010252 TRIM33 953 _GK(ac)TAQGLSPVDQR_ 1.00
300 IPI00554798 HIST1H2BM 17 _K(ac)AINK(ac)AQK_ 1.00
301 IPI00554798 HIST1H2BM 21 _K(ac)AINK(ac)AQK_ 1.00
302 IPI00183626 PTBP1 266 _LTSLNVK(ac)YNNDK_ 1.00
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303 IPI00453473 HIST1H4H 92 _TVTAMDVVYALK(ac)R_ 1.00
304 IPI00013297 PDAP1 132 _MHLAGK(ac)TEQAK_ 1.00
305 IPI00020008 NEDD8 6 _VK(ac)TLTGK_ 1.00
306 IPI00911094 DAP 29 _IVQK(ac)HPHTGDTK_ 1.00
307 IPI00333541 FLNA 92 _K(ac)HNQRPTFR_ 1.00
308 IPI00883857 HNRNPU 516 _TTWVTK(ac)HAAENPGK_ 1.00
309 IPI00029631 ERH 12 _(ac)SHTILLVQPTK(ac)RPEGR_ 1.00
310 IPI00306723 CEBPZ 695 _QLNK(ac)YDPFSR_ 1.00
311 IPI00465070 HIST1H3F 57 _YQK(ac)STELLIR_ 1.00
312 IPI00418169 ANXA2 245 _SVPHLQK(ac)VFDR_ 1.00
313 IPI00009373 MEAF6 69 _YLTNQK(ac)NSNSK(ac)NDR_ 1.00
314 IPI00183626 PTBP1 436 _ITLSK(ac)HQNVQLPR_ 1.00
315 IPI00299573 RPL7A 101 _LAHK(ac)YRPETK_ 1.00
316 IPI00290566 TCP1 400 _SLHDALCVVK(ac)R_ 1.01
317 IPI00000684 UAP1 180 _EFFTK(ac)HK_ 1.01
318 IPI00025366 CS 366 _EFALK(ac)HLPNDPMFK_ 1.01
319 IPI00029731 RPL35A 95 _SNLPAK(ac)AIGHR_ 1.01
320 IPI00019927 PSMD7 199 _ITNQVHGLK(ac)GLNSK_ 1.01
321 IPI00894409 176 _QGDGK(ac)WHLVYR_ 1.01
322 IPI00241860 MIPEP 231 _IEK(ac)HLLPEHIR_ 1.01
323 IPI00465248 ENO1 330 _IAK(ac)AVNEK_ 1.01
324 IPI00453473 HIST1H4H 13 _GLGK(ac)GGAK(ac)R_ 1.01
325 IPI00413451 SERPINB6 165 _K(ac)HINTWVAEK_ 1.01
326 IPI00796333 284 _ALSDHHIYLEGTLLK(ac)PNMVTPGHACTQK_ 1.01
327 IPI00465248 ENO1 71 _AVEHINK(ac)TIAPALVSK_ 1.02
328 IPI00644712 XRCC6 605 _KQELLEALTK(ac)HFQD_ 1.02
329 IPI00219217 LDHB 156 _LSGLPK(ac)HR_ 1.02
330 IPI00550021 RPL3 373 _FIDTTSK(ac)FGHGR_ 1.02
331 IPI00644712 XRCC6 565 _VEYSEEELK(ac)THISK_ 1.02
332 IPI00883857 HNRNPU 814 _NQSQGYNQWQQGQFWGQK(ac)PWSQHYHQGYY_ 1.02
333 IPI00000494 RPL5 43 _NK(ac)YNTPK_ 1.03
334 IPI00414676 HSP90AB1 275 _EK(ac)YIDQEELNK_ 1.03
335 IPI00396627 ELAC2 646 _HCK(ac)HAFGCALVHTSGWK_ 1.03
336 IPI00395627 CACYBP 85 _ISNYGWDQSDK(ac)FVK_ 1.03
337 IPI00412607 RPL35 97 _LNK(ac)HEENLK_ 1.03
338 IPI00152906 HIST1H2BD 109 _LLLPGELAK(ac)HAVSEGTK_ 1.03
339 IPI00302927 CCT4 321 _MK(ac)IMVIK_ 1.03
340 IPI00006164 ILKAP 210 _QASSQK(ac)PAWK_ 1.03
341 IPI00465070 HIST1H3F 19 _K(ac)QLATK(ac)AAR_ 1.04
342 IPI00000874 PRDX1 185 _HGEVCPAGWKPGSDTIK(ac)PDVQK_ 1.04
343 IPI00328748 MANF 123 _DSQICELK(ac)YDK_ 1.04
344 IPI00247583 RPL21 97 _IEHIK(ac)HSK_ 1.04
345 IPI00418169 ANXA2 166 _VYK(ac)EMYK_ 1.04
346 IPI00023647 UBA6 1014 _LVK(ac)PTTEK_ 1.04
347 IPI00026302 RPL31 70 _LNK(ac)AVWAK_ 1.04
348 IPI00453473 HIST1H4H 32 _DNIQGITK(ac)PAIR_ 1.04
349 IPI00479946 STIP1 293 _DFDTALK(ac)HYDK_ 1.04
350 IPI00301364 SKP1 66 _VIQWCTHHK(ac)DDPPPPEDDENKEK_ 1.04
351 IPI00000684 UAP1 182 _HK(ac)YFGLK_ 1.04
352 IPI00930688 TUBA1B 394 _LDHK(ac)FDLMYAK_ 1.04
353 IPI00465248 ENO1 89 _LNVTEQEK(ac)IDK_ 1.04
354 IPI00005613 U2AF1 175 _GGFCNFMHLK(ac)PISR_ 1.04
355 IPI00784090 CCT8 318 _LNSK(ac)WDLR_ 1.05
356 IPI00438229 TRIM28 340 _IQK(ac)HQEHILR_ 1.05
357 IPI00023860 NAP1L1 82 _VNALK(ac)NLQVK_ 1.05
358 IPI00218918 ANXA1 312 _SEIDM(ox)NDIK(ac)AFYQK_ 1.05
359 IPI00013122 CDC37 154 _TFVEK(ac)YEK_ 1.05
360 IPI00074893 ZNF512B 843 _K(ac)NLAGGK(ac)K(ac)R_ 1.05
361 IPI00074893 ZNF512B 842 _K(ac)NLAGGK(ac)K(ac)R_ 1.05
362 IPI00074893 ZNF512B 836 _K(ac)NLAGGK(ac)K(ac)R_ 1.05
363 IPI00789551 MATR3 473 _VHLSQK(ac)YK_ 1.06
364 IPI00219568 PGK2 267 _IVK(ac)DIM(ox)AK_ 1.06
365 IPI00024067 CLTC 907 _VVGK(ac)YCEK_ 1.06
366 IPI00909853 DDT 33 _LCAAAASILGK(ac)PADR_ 1.06
367 IPI00008274 CAP1 282 _THK(ac)NPALK_ 1.06
368 IPI00027626 CCT6A 381 _GPNK(ac)HTLTQIK_ 1.06
369 IPI00296337 PRKDC 1141 _K(ac)HVSLNK_ 1.06
370 IPI00022744 CSE1L 425 _NPSVNWK(ac)HK_ 1.07
371 IPI00023860 NAP1L1 194 _NVDLLSDMVQEHDEPILK(ac)HLK_ 1.07
372 IPI00000874 PRDX1 192 _SK(ac)EYFSK_ 1.07
373 IPI00031564 GGCT 118 _VATQEGK(ac)EITCR_ 1.07
374 IPI00169383 PGK1 267 _IVK(ac)DLMSK_ 1.07
375 IPI00152906 HIST1H2BD 44 _ESYSVYVYK(ac)VLK_ 1.07
376 IPI00022334 OAT 102 _IVNALK(ac)SQVDK_ 1.07
377 IPI00479946 STIP1 372 _DAIHFYNK(ac)SLAEHR_ 1.07
378 IPI00299608 PSMD1 720 _VINDK(ac)HDDVMAK_ 1.08
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379 IPI00465070 HIST1H3F 80 _EIAQDFK(ac)TDLR_ 1.08
380 IPI00465248 ENO1 193 _IGAEVYHNLK(ac)NVIK_ 1.08
381 IPI00008524 PABPC1 108 _NLDK(ac)SIDNK_ 1.08
382 IPI00604590 puf 125 _VMLGETNPADSK(ac)PGTIR_ 1.08
383 IPI00220834 XRCC5 265 _IAAYK(ac)SILQER_ 1.08
384 IPI00328798 BCL9L 36 _GHCPPAPAK(ac)PMHPENK_ 1.08
385 IPI00453473 HIST1H4H 17 _GLGK(ac)GGAK(ac)R_ 1.08
386 IPI00015911 DLD 430 _AK(ac)TNADTDGMVK_ 1.08
387 IPI00013415 RPS7 155 _LIK(ac)VHLDK_ 1.08
388 IPI00789159 RPL23A 148 _HQIK(ac)QAVK_ 1.09
389 IPI00396485 EEF1A1 439 _QTVAVGVIK(ac)AVDK_ 1.09
390 IPI00843975 EZR 258 _FVIK(ac)PIDK_ 1.09
391 IPI00430472 ASCC3 572 _ELTGDMQLSK(ac)SEILR_ 1.09
392 IPI00003865 HSPA8 524 _MVQEAEK(ac)YK_ 1.09
393 IPI00010740 SFPQ 232 _PGGGPGLSTPGGHPK(ac)PPHR_ 1.09
394 IPI00419833 HIST1H2BK 121 _AVTK(ac)YTSAK_ 1.09
395 IPI00883857 HNRNPU 609 _AVVVCPK(ac)DEDYK_ 1.09
396 IPI00429190 RAB11A 224 _IVSQK(ac)QMSDR_ 1.10
397 IPI00299149 SUMO2 45 _LMK(ac)AYCER_ 1.10
398 IPI00056495 ARL11 31 _TTLLYK(ac)LK_ 1.10
399 IPI00015018 PPA1 228 _STHDHWK(ac)ALVTK_ 1.10
400 IPI00916847 99 _FDFLCQYHK(ac)PASK_ 1.10
401 IPI00930174 HIST2H2BF 17 _K(ac)GSK(ac)K(ac)AVTK_ 1.10
402 IPI00930174 HIST2H2BF 21 _K(ac)AVTK(ac)VQK_ 1.10
403 IPI00021828 CSTB 91 _AK(ac)HDELTYF_ 1.10
404 IPI00018278 H2AFV 116 _ATIAGGGVIPHIHK(ac)SLIGK_ 1.10
405 IPI00005511 PHF5A 3 _(ac)AK(ac)HHPDLIFCR_ 1.10
406 IPI00604590 puf 264 _NIIHGSDSVK(ac)SAEK_ 1.10
407 IPI00646304 PPIB 116 _GDGTGGK(ac)SIYGER_ 1.10
408 IPI00219525 PGD 38 _TVSK(ac)VDDFLANEAK_ 1.10
409 IPI00023234 UBA2 164 _GVTECYECHPK(ac)PTQR_ 1.10
410 IPI00871535 SPTAN1 2057 _HVQSK(ac)AIEAR_ 1.10
411 IPI00217030 RPS4X 53 _LK(ac)YALTGDEVK_ 1.11
412 IPI00219029 GOT1 214 _QIASVMK(ac)HR_ 1.11
413 IPI00183695 S100A10 23 _FAGDK(ac)GYLTK_ 1.11
414 IPI00013290 HDGF2 282 _KPAEK(ac)PLPK_ 1.11
415 IPI00005161 ARPC2 290 _EMK(ac)TITGK_ 1.11
416 IPI00007188 SLC25A5 23 _DFLAGGVAAAISK(ac)TAVAPIER_ 1.11
417 IPI00412579 RPL10A 91 _AVDIPHMDIEALK(ac)K_ 1.11
418 IPI00301311 SET 154 _EFHLNESGDPSSK(ac)STEIK_ 1.11
419 IPI00003865 HSPA8 597 _NQTAEKEEFEHQQK(ac)ELEK_ 1.12
420 IPI00219018 GAPDH 61 _FHGTVK(ac)AENGK_ 1.12
421 IPI00744692 TALDO1 321 _FAADAVK(ac)LER_ 1.12
422 IPI00220170 WNT9A 246 _HK(ac)YETALK_ 1.13
423 IPI00644322 PHF15 54 _LPSSTK(ac)SGWPR_ 1.13
424 IPI00025329 RPL19 128 _VK(ac)GNVFK_ 1.13
425 IPI00016801 GLUD1 390 _QLTK(ac)SNAPR_ 1.13
426 IPI00216298 TXN 39 _MIK(ac)PFFHSLSEK_ 1.13
427 IPI00438229 TRIM28 266 _LGDK(ac)HATLQK_ 1.13
428 IPI00178431 RECQL 637 _AANMLQQSGSK(ac)NTGAK_ 1.13
429 IPI00295741 CTSB 220 _ICEPGYSPTYK(ac)QDK_ 1.13
430 IPI01024911 PSMA7 104 _YK(ac)YGYEIPVDMLCK_ 1.13
431 IPI00020984 CANX 252 _TGIYEEK(ac)HAK_ 1.14
432 IPI00027626 CCT6A 377 _SVTLLIK(ac)GPNK_ 1.14
433 IPI00646304 PPIB 131 _LK(ac)HYGPGWVSMANAGK_ 1.14
434 IPI00328257 AP1B1 318 _RPEILK(ac)HEMK_ 1.14
435 IPI00007423 ANP32B 101 _LK(ac)DISTLEPLK_ 1.14
436 IPI00152906 HIST1H2BD 13 _K(ac)GSK(ac)K(ac)AVTK_ 1.14
437 IPI00152906 HIST1H2BD 16 _K(ac)GSK(ac)K(ac)AVTK_ 1.14
438 IPI00909484 RAN 198 _AVK(ac)YVECSALTQK_ 1.14
439 IPI00220301 PRDX6 209 _GVFTK(ac)ELPSGK_ 1.14
440 IPI00219018 GAPDH 139 _VIISAPSADAPM(ox)FVMGVNHEK(ac)YDNSLK_ 1.14
441 IPI00012007 AHCY 188 _SK(ac)FDNLYGCR_ 1.15
442 IPI00465028 TPI1 231 _GWLK(ac)SNVSDAVAQSTR_ 1.15
443 IPI00465028 TPI1 193 _VIADNVK(ac)DWSK_ 1.15
444 IPI00219018 GAPDH 194 _TVDGPSGK(ac)LWR_ 1.15
445 IPI00017381 RFC4 13 _GTSISTK(ac)PPLTK_ 1.15
446 IPI00027107 TUFM 94 _K(ac)YEEIDNAPEER_ 1.15
447 IPI00301311 SET 59 _VEQK(ac)YNK_ 1.16
448 IPI00412579 RPL10A 106 _K(ac)YDAFLASESLIK_ 1.16
449 IPI00465070 HIST1H3F 123 _VTIMPK(ac)DIQLAR_ 1.16
450 IPI00789101 PTGES3 37 _DVNVNFEK(ac)SK_ 1.16
451 IPI00152906 HIST1H2BD 17 _K(ac)GSK(ac)K(ac)AVTK_ 1.16
452 IPI00396485 EEF1A1 255 _LPLQDVYK(ac)IGGIGTVPVGR_ 1.16
453 IPI00942979 TKT 232 _AFGQAK(ac)HQPTAIIAK_ 1.17
454 IPI00396485 EEF1A1 244 _PTDK(ac)PLR_ 1.17
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455 IPI00465248 ENO1 64 _GVSK(ac)AVEHINK_ 1.17
456 IPI00302927 CCT4 319 _DALSDLALHFLNK(ac)MK_ 1.17
457 IPI00002270 C6orf211 40 _HK(ac)SEFFEK_ 1.17
458 IPI00440493 ATP5A1 305 _DNGK(ac)HALIIYDDLSK_ 1.17
459 IPI00020436 RAB11B 179 _IVSQK(ac)QIADR_ 1.17
460 IPI00183695 S100A10 28 _GYLTK(ac)EDLR_ 1.17
461 IPI00152906 HIST1H2BD 21 _K(ac)AVTK(ac)AQK_ 1.17
462 IPI00790305 PCNP 85 _SAEEEAADLPTK(ac)PTK_ 1.18
463 IPI00000874 PRDX1 168 _LVQAFQFTDK(ac)HGEVCPAGWKPGSDTIKPDVQK_ 1.18
464 IPI00465361 RPL13 174 _VITEEEK(ac)NFK_ 1.18
465 IPI00003362 HSPA5 340 _STMK(ac)PVQK_ 1.18
466 IPI00479946 STIP1 115 _TVDLK(ac)PDWGK_ 1.18
467 IPI00848161 BAT1 183 _NK(ac)SLNLK_ 1.18
468 IPI00294186 LACTB 243 _MMK(ac)ENVAFEQEK_ 1.18
469 IPI00964764 SDHA 287 _YAPVAK(ac)DLASR_ 1.18
470 IPI00217975 LMNB1 532 _VILK(ac)NSQGEEVAQR_ 1.19
471 IPI00296337 PRKDC 832 _VVLK(ac)HLK_ 1.19
472 IPI00003949 UBE2N 92 _ICLDILK(ac)DK_ 1.19
473 IPI00025084 CAPNS1 179 _WQAIYK(ac)QFDTDR_ 1.19
474 IPI00011916 AIMP2 252 _EK(ac)AAVFR_ 1.19
475 IPI00025252 PDIA3 214 _PSHLTNK(ac)FEDK_ 1.19
476 IPI00644322 PHF15 314 _MEPITK(ac)ISHIPASR_ 1.19
477 IPI00292471 ARAP2 391 _ISEDK(ac)VEDIWIPR_ 1.19
478 IPI00396485 EEF1A1 392 _LEDGPK(ac)FLK_ 1.19
479 IPI00185374 PSMD12 98 _SQLK(ac)QAVAK_ 1.19
480 IPI00003865 HSPA8 601 _ELEK(ac)VCNPIITK_ 1.20
481 IPI00414676 HSP90AB1 607 _IMK(ac)AQALR_ 1.20
482 IPI00012480 ARAP2 403 _VK(ac)TVPLVSK_ 1.20
483 IPI00924608 VPS13D 4010 _LPLDLK(ac)ALK_ 1.20
484 IPI00844264 694 _GDCLQK(ac)GESVK_ 1.20
485 IPI00007402 IPO7 1013 _MIEK(ac)HGGYK_ 1.20
486 IPI00152906 HIST1H2BD 121 _AVTK(ac)YTSSK_ 1.20
487 IPI00020510 CISD1 68 _IVHAFDMEDLGDK(ac)AVYCR_ 1.21
488 IPI00646304 PPIB 209 _IEVEK(ac)PFAIAK_ 1.21
489 IPI00291467 SLC25A6 23 _DFLAGGIAAAISK(ac)TAVAPIER_ 1.21
490 IPI00220834 XRCC5 648 _EEAIK(ac)FSEEQR_ 1.22
491 IPI00604620 NCL 398 _TLLAK(ac)NLPYK_ 1.22
492 IPI00027463 S100A6 35 _ELK(ac)ELIQK_ 1.22
493 IPI00007927 SMC2 320 _SQSAFDLK(ac)K_ 1.23
494 IPI00784090 CCT8 534 _PAGGPK(ac)PPSGK_ 1.23
495 IPI00418169 ANXA2 297 _LYDSMK(ac)GK_ 1.23
496 IPI00031522 HADHA 406 _GQQQVFK(ac)GLNDK_ 1.23
497 IPI00178352 FLNC 2685 _TPCEEVYVK(ac)HMGNR_ 1.23
498 IPI00016801 GLUD1 480 _FGK(ac)HGGTIPIVPTAEFQDR_ 1.24
499 IPI00646304 PPIB 165 _TAWLDGK(ac)HVVFGK_ 1.24
500 IPI00296337 PRKDC 3642 _EFDK(ac)HFGK_ 1.24
501 IPI00902560 VDAC2 89 _YK(ac)WCEYGLTFTEK_ 1.24
502 IPI00009931 HDHD3 15 _LLTWDVK(ac)DTLLR_ 1.24
503 IPI00008274 CAP1 178 _K(ac)HVDWVK_ 1.24
504 IPI00790685 RALYL 183 _VAVTTTRRGK(ac)GVFSMK_ 1.24
505 IPI00019226 BRD8 1110 _K(ac)TLLPVWK(ac)M(ox)IASHR_ 1.25
506 IPI00019226 BRD8 1117 _K(ac)TLLPVWK(ac)M(ox)IASHR_ 1.25
507 IPI00290204 SNRNP70 162 _DMHSAYK(ac)HADGK_ 1.25
508 IPI00329512 SNRPN 32 _IFIGTFK(ac)AFDK_ 1.25
509 IPI00221089 RPS13 34 _LTSDDVK(ac)EQIYK_ 1.25
510 IPI00514393 RNPC3 275 _TIK(ac)QRHVR_ 1.25
511 IPI00020599 CALR 41 _WIESK(ac)HK_ 1.26
512 IPI00848328 PTBP1 234 _VTSAQK(ac)HVLHVQLNRPNKR_ 1.26
513 IPI00219018 GAPDH 263 _VVK(ac)QASEGPLK_ 1.26
514 IPI00549564 ACSS2 431 _LLMK(ac)FGDEPVTK_ 1.26
515 IPI00183695 S100A10 57 _IMK(ac)DLDQCR_ 1.26
516 IPI00848161 BAT1 188 _SLNLK(ac)HIK_ 1.26
517 IPI00744692 TALDO1 286 _AAQASDLEK(ac)IHLDEK_ 1.27
518 IPI00003482 DECR1 246 _TK(ac)GAFSR_ 1.27
519 IPI00028004 PSMB3 77 _LNLYELK(ac)EGR_ 1.27
520 IPI00644037 TECR 37 _LCFLDK(ac)VEPHATIAEIK_ 1.27
521 IPI00006482 ATP1A1 843 _TDK(ac)LVNER_ 1.27
522 IPI00026848 LRPAP1 287 _HFEAK(ac)IEK_ 1.27
523 IPI00307430 IFT122 212 _NK(ac)NGEEKVKIER_ 1.27
524 IPI00011200 PHGDH 289 _ALVDHENVISCPHLGASTK(ac)EAQSR_ 1.27
525 IPI00396485 EEF1A1 41 _TIEK(ac)FEK_ 1.28
526 IPI00186290 EEF2 275 _FSK(ac)SATSPEGK_ 1.28
527 IPI00306301 PDHA1 359 _SKSDPIMLLK(ac)DR_ 1.28
528 IPI00644712 XRCC6 463 _MK(ac)AIVEK_ 1.28
529 IPI00030275 TRAP1 424 _LIK(ac)FFIDQSK_ 1.29
530 IPI00025252 PDIA3 417 _YK(ac)ELGEK_ 1.29
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531 IPI00015911 DLD 104 _ALLNNSHYYHMAHGK(ac)DFASR_ 1.29
532 IPI00010896 ENSG00000226651 135 _GLLK(ac)ALK_ 1.29
533 IPI00513827 ACADM 451 _EHIDK(ac)YK_ 1.30
534 IPI00217975 LMNB1 271 _LYKEELEQTYHAK(ac)LENAR_ 1.30
535 IPI00217240 WDR75 466 _SEQPTLVTASK(ac)DGYFK_ 1.30
536 IPI01013939 CTTN 87 _ASHGYGGK(ac)FGVEQDR_ 1.30
537 IPI01022656 DDX17 286 _STCIYGGAPK(ac)GPQIR_ 1.30
538 IPI00604620 NCL 572 _SQPSK(ac)TLFVK_ 1.30
539 IPI00908949 TARS 246 _EK(ac)QAFER_ 1.30
540 IPI00646917 NUDT21 23 _GVTQFGNK(ac)YIQQTK_ 1.31
541 IPI00167941 MDN1 3482 _SGGK(ac)ELEGK_ 1.31
542 IPI00025252 PDIA3 218 _FEDK(ac)TVAYTEQK_ 1.31
543 IPI00796333 201 _DGADFAK(ac)WR_ 1.31
544 IPI01009314 CREBBP 1622 _K(ac)TNK(ac)NK(ac)SSISR_ 1.31
545 IPI00178440 EEF1B2 60 _WYNHIK(ac)SYEK_ 1.31
546 IPI00298289 RTN4 285 _YSNSALGHVNCTIK(ac)ELR_ 1.32
547 IPI00022386 TXNDC9 116 _HLAILSK(ac)K_ 1.32
548 IPI00025252 PDIA3 226 _TVAYTEQK(ac)MTSGK_ 1.32
549 IPI00916847 268 _IK(ac)EWVDK_ 1.32
550 IPI00147874 NANS 52 _ECGADCAK(ac)FQK_ 1.32
551 IPI00883857 HNRNPU 352 _HLYTK(ac)DIDIHEVR_ 1.32
552 IPI00241860 MIPEP 555 _HYQTGQPLPK(ac)NMVSR_ 1.32
553 IPI00239077 HINT1 21 _PGGDTIFGK(ac)IIR_ 1.32
554 IPI00008982 ALDH18A1 59 _THGK(ac)SFAHR_ 1.32
555 IPI00549248 NPM1 27 _ADK(ac)DYHFK_ 1.33
556 IPI00025252 PDIA3 415 _NLEPK(ac)YK_ 1.33
557 IPI00007641 IRAK4 34 _K(ac)LAVAIK_ 1.33
558 IPI00221093 19 _VIIEK(ac)YYTR_ 1.33
559 IPI00015911 DLD 143 _ALTGGIAHLFK(ac)QNK_ 1.33
560 IPI00420014 SNRNP200 1552 _PVYHAITK(ac)HSPK_ 1.33
561 IPI00219068 NAA30 233 _LITK(ac)DLSEPYSIYTYR_ 1.33
562 IPI00555744 RPL14 187 _VPAQK(ac)ATGQK_ 1.34
563 IPI00030820 MRPL47 144 _VVDSMDALDK(ac)VVQER_ 1.34
564 IPI00027107 TUFM 91 _ILAEGGGAK(ac)FK_ 1.35
565 IPI00008708 RSL1D1 120 _LLNK(ac)HGIK_ 1.35
566 IPI01015120 27 _GVQK(ac)HQDDLQDVIGR_ 1.35
567 IPI00016801 GLUD1 84 _GASIVEDK(ac)LVEDLR_ 1.35
568 IPI00020599 CALR 238 _IDDPTDSKPEDWDK(ac)PEHIPDPDAK_ 1.35
569 IPI00333541 FLNA 700 _TGVAVNKPAEFTVDAK(ac)HGGK_ 1.35
570 IPI00291467 SLC25A6 272 _AFFK(ac)GAWSNVLR_ 1.36
571 IPI00219018 GAPDH 254 _PAK(ac)YDDIKK_ 1.37
572 IPI00646015 ACOT9 112 _EK(ac)YLTVQNTVR_ 1.37
573 IPI00910513 GSPT1 346 _EHAMLAK(ac)TAGVK_ 1.37
574 IPI00551002 NDEL1 317 _K(ac)VGALESK_ 1.38
575 IPI00549248 NPM1 267 _VEAK(ac)FINYVK_ 1.38
576 IPI00903062 CYFIP1 1190 _VQK(ac)HDGKDEIIK_ 1.38
577 IPI00296374 ZFPL1 234 _TPGLHGDCDDDK(ac)YR_ 1.38
578 IPI00219034 NDUFA8 38 _AAAHHYGAQCDK(ac)PNK_ 1.38
579 IPI00396485 EEF1A1 172 _YEEIVK(ac)EVSTYIK_ 1.38
580 IPI00549248 NPM1 32 _DYHFK(ac)VDNDENEHQLSLR_ 1.39
581 IPI00646304 PPIB 171 _HVVFGK(ac)VLEGMEVVR_ 1.39
582 IPI00147874 NANS 79 _HSWGK(ac)TYGEHK_ 1.39
583 IPI00008752 MT1G 52 _CAQGCICK(ac)GASEK_ 1.39
584 IPI00016801 GLUD1 503 _ISGASEK(ac)DIVHSGLAYTMER_ 1.40
585 IPI00782992 SRRM2 845 _VK(ac)SGTPPR_ 1.40
586 IPI00465070 HIST1H3F 15 _K(ac)STGGK(ac)APR_ 1.41
587 IPI00465070 HIST1H3F 10 _K(ac)STGGK(ac)APR_ 1.41
588 IPI00000875 484 _AFNQGK(ac)IFK_ 1.41
589 IPI00465070 HIST1H3F 24 _QLATK(ac)AAR_ 1.41
590 IPI00306369 NSUN2 84 _ITGYK(ac)SHAK_ 1.41
591 IPI00008708 RSL1D1 426 _AAESETPGK(ac)SPEK_ 1.42
592 IPI00395462 35 _K(ac)HDSGAADLER_ 1.42
593 IPI00293564 HMGCL 48 _DGLQNEK(ac)NIVSTPVK_ 1.42
594 IPI00022498 MT2A 51 _CAQGCICK(ac)GASDK_ 1.42
595 IPI00032140 SERPINH1 217 _FHHK(ac)MVDNR_ 1.42
596 IPI00178431 RECQL 206 _LEK(ac)AYEAR_ 1.43
597 IPI00216308 VDAC1 224 _FGIAAK(ac)YQIDPDACFSAK_ 1.43
598 IPI00018627 NAA50 34 _LNQVIFPVSYNDK(ac)FYK_ 1.43
599 IPI00216952 LMNA 265 _ELEK(ac)TYSAK_ 1.44
600 IPI00902560 VDAC2 87 _VTGTLETK(ac)YK_ 1.44
601 IPI00025491 EIF4A1 174 _YLSPK(ac)YIK_ 1.44
602 IPI00028946 RTN3 217 _DQTK(ac)SIVEK_ 1.44
603 IPI00306301 PDHA1 101 _EDGLK(ac)YYR_ 1.45
604 IPI00028031 ACADVL 685 _SISK(ac)ALVER_ 1.45
605 IPI00033217 AASS 138 _LIDYEK(ac)MVDHR_ 1.45
606 IPI00964764 SDHA 499 _LYGDLK(ac)HLK_ 1.45
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607 IPI00942979 TKT 260 _ESWHGK(ac)PLPK_ 1.45
608 IPI00002520 SHMT2 469 _LQDFK(ac)SFLLK_ 1.46
609 IPI00018627 NAA50 37 _FYK(ac)DVLEVGELAK_ 1.46
610 IPI00002520 SHMT2 181 _IMGLDLPDGGHLTHGYMSDVK(ac)R_ 1.46
611 IPI00248651 REV3L 1227 _KHTTLK(ac)DEK_ 1.47
612 IPI00296053 FH 61 _IEYDTFGELK(ac)VPNDK_ 1.47
613 IPI00298423 PDHX 321 _QDLVK(ac)DDIK_ 1.47
614 IPI00030702 IDH3A 343 _SLTK(ac)DLGGNAK_ 1.48
615 IPI00401264 ERP44 106 _ISK(ac)YPTLK_ 1.48
616 IPI00220403 HIST1H2BB 17 _K(ac)GSK(ac)K(ac)AITK_ 1.48
617 IPI00008753 MT1X 51 _CAQGCICK(ac)GTSDK_ 1.49
618 IPI00478410 ATP5C1 83 _ADIK(ac)GPEDK_ 1.49
619 IPI00294779 VDAC3 62 _ASGNLETK(ac)YK_ 1.49
620 IPI00845461 ATL3 418 _HCEFK(ac)QLALDHFK_ 1.49
621 IPI00922415 SSBP1 81 _SGDSEVYQLGDVSQK(ac)TTWHR_ 1.50
622 IPI00178352 FLNC 734 _CSYVPTK(ac)PIK_ 1.51
623 IPI00604620 NCL 646 _VTLDWAK(ac)PK_ 1.51
624 IPI00015911 DLD 445 _ILGQK(ac)STDR_ 1.51
625 IPI00787827 PITRM1 771 _K(ac)HLLNGDNMR_ 1.51
626 IPI00029056 SEPHS1 27 _FTELK(ac)GTGCK_ 1.51
627 IPI00744851 HMGA1 15 _SSQPLASK(ac)QEK_ 1.51
628 IPI00787827 PITRM1 760 _IAEMTDIK(ac)PILR_ 1.52
629 IPI00783097 GARS 224 _AHLQK(ac)LMSDK_ 1.52
630 IPI00100460 DARS2 635 _VSK(ac)PTDSK_ 1.52
631 IPI00555902 OCIAD2 41 _AEISK(ac)IMR_ 1.52
632 IPI00910267 GOT2 302 _QWLQEVK(ac)GMADR_ 1.52
633 IPI00064744 192 _LPGALWVKERLPGK(ac)GEK_ 1.52
634 IPI00412404 SUPV3L1 220 _TYHAIQK(ac)YFSAK_ 1.52
635 IPI00005537 SLC25A10 138 _LTEAK(ac)PVDK_ 1.53
636 IPI00102575 ATAD5 484 _K(ac)TLDTGAIPGK_ 1.53
637 IPI00032140 SERPINH1 319 _GVVEVTHDLQK(ac)HLAGLGLTEAIDK_ 1.54
638 IPI00217466 HIST1H1D 86 _LGLK(ac)SLVSK_ 1.54
639 IPI00165092 YARS2 355 _LAAEVTK(ac)LVHGR_ 1.54
640 IPI00012912 CPT2 453 _GGK(ac)EFLK_ 1.54
641 IPI00001539 ACAA2 181 _EECDK(ac)YALQSQQR_ 1.55
642 IPI00026516 OXCT1 463 _CTLPLTGK(ac)QCVNR_ 1.55
643 IPI00465248 ENO1 343 _SCNCLLLK(ac)VNQIGSVTESLQACK_ 1.55
644 IPI00719752 EIF3B 257 _LDK(ac)QHTFR_ 1.56
645 IPI00784154 HSPD1 125 _SIAK(ac)EGFEK_ 1.56
646 IPI00291467 SLC25A6 166 _ITK(ac)SDGIR_ 1.57
647 IPI00216308 VDAC1 61 _VTGSLETK(ac)YR_ 1.57
648 IPI00216746 HNRNPK 405 _DLAGSIIGK(ac)GGQR_ 1.57
649 IPI00007188 SLC25A5 166 _IYK(ac)SDGIK_ 1.57
650 IPI00015911 DLD 166 _NQVTATK(ac)ADGGTQVIDTK_ 1.58
651 IPI00007074 YARS 146 _LSSVVTQHDSK(ac)K_ 1.58
652 IPI00298289 RTN4 355 _NVK(ac)DAMAK_ 1.58
653 IPI00015911 DLD 267 _ILQK(ac)QGFK_ 1.58
654 IPI00216298 TXN 8 _QIESK(ac)TAFQEALDAAGDK_ 1.58
655 IPI00024913 C21orf33 219 _ALGAK(ac)HCVK_ 1.58
656 IPI00646015 ACOT9 416 _EVPLVFPK(ac)TYGESMLYLDGQR_ 1.58
657 IPI00291467 SLC25A6 92 _YFPTQALNFAFK(ac)DK_ 1.59
658 IPI00026089 SF3B1 1067 _ICFELLELLK(ac)AHK_ 1.59
659 IPI00025273 GART 156 _ASGLAAGK(ac)GVIVAK_ 1.60
660 IPI00009373 MEAF6 74 _YLTNQK(ac)NSNSK(ac)NDR_ 1.60
661 IPI00643435 ATAD3A 539 _MYFDK(ac)YVLKPATEGK_ 1.61
662 IPI00784154 HSPD1 156 _GVMLAVDAVIAELK(ac)K_ 1.62
663 IPI00019912 HSD17B4 565 _FAK(ac)PVYPGQTLQTEMWK_ 1.63
664 IPI00180764 MYST2 199 _CPTPGCNSLGHLTGK(ac)HER_ 1.63
665 IPI00167535 EP400 3155 _TPTK(ac)PPCQ_ 1.63
666 IPI00553153 ATPIF1 72 _K(ac)HHEEEIVHHK_ 1.64
667 IPI00784154 HSPD1 31 _DVK(ac)FGADAR_ 1.64
668 IPI00291646 MTHFD1L 517 _ILHENTQTDK(ac)ALYNR_ 1.64
669 IPI00003918 RPL4 411 _KPAPEK(ac)KPAEK_ 1.65
670 IPI00296053 FH 66 _VPNDK(ac)YYGAQTVR_ 1.65
671 IPI00900293 FLNB 2201 _FVPQEMGVHTVSVK(ac)YR_ 1.65
672 IPI00470502 PPA2 291 _STHQCWK(ac)ALLMK_ 1.65
673 IPI00024993 ECHS1 118 _FLK(ac)HWDHLTQVK_ 1.66
674 IPI00453473 HIST1H4H 6 _GK(ac)GGK(ac)GLGK(ac)GGAK_ 1.66
675 IPI00298289 RTN4 364 _IQAK(ac)IPGLK_ 1.66
676 IPI00030275 TRAP1 324 _YVAQAHDK(ac)PR_ 1.67
677 IPI00026519 PPIF 73 _ADVVPK(ac)TAENFR_ 1.68
678 IPI00002966 HSPA4 766 _SK(ac)EIEAK_ 1.68
679 IPI00910781 GPI 252 _DPSAVAK(ac)HFVALSTNTTK_ 1.69
680 IPI00215911 APEX1 197 _FLK(ac)GLASR_ 1.69
681 IPI00306301 PDHA1 351 _SK(ac)SDPIMLLK_ 1.70
682 IPI00000875 197 _ILGLLDAYLK(ac)TR_ 1.70
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683 IPI00815713 TCOF1 432 _PSGK(ac)APQVR_ 1.70
684 IPI00219160 RPL34 36 _IVYLYTK(ac)K_ 1.71
685 IPI00018278 H2AFV 8 _AGGK(ac)AGK(ac)DSGK(ac)AK_ 1.71
686 IPI00018278 H2AFV 12 _AGGK(ac)AGK(ac)DSGK(ac)AK_ 1.71
687 IPI00018278 H2AFV 5 _AGGK(ac)AGK(ac)DSGK(ac)AK_ 1.71
688 IPI00100630 MLLT1 252 _AAFK(ac)EPK_ 1.74
689 IPI00007611 ATP5O 192 _IGEK(ac)YVDMSVK_ 1.74
690 IPI00028635 RPN2 311 _LEHAK(ac)SVASR_ 1.74
691 IPI00744711 PNPT1 289 _YTHK(ac)LAMER_ 1.75
692 IPI00304925 HSPA1A 246 _LVNHFVEEFK(ac)R_ 1.75
693 IPI00306159 MECR 267 _LALNCVGGK(ac)SSTELLR_ 1.76
694 IPI00011396 GRIK2 847 _SK(ac)K(ac)NAQLEK_ 1.77
695 IPI00011396 GRIK2 848 _SK(ac)K(ac)NAQLEK_ 1.77
696 IPI00396485 EEF1A1 179 _EVSTYIK(ac)K_ 1.77
697 IPI00304925 HSPA1A 512 _LSK(ac)EEIER_ 1.78
698 IPI00029133 ATP5F1 233 _HVVQSISTQQEK(ac)ETIAK_ 1.79
699 IPI00219525 PGD 59 _VVGAQSLK(ac)EMVSK_ 1.80
700 IPI00001734 PSAT1 363 _GDDALEK(ac)R_ 1.81
701 IPI00220487 ATP5H 85 _VPVPEDK(ac)YTAQVDAEEKEDVK_ 1.81
702 IPI00007765 HSPA9 76 _QAK(ac)VLENAEGAR_ 1.81
703 IPI00291006 MDH2 157 _K(ac)HGVYNPNK_ 1.81
704 IPI00018206 GOT2 296 _VGAFTMVCK(ac)DADEAK_ 1.81
705 IPI00015911 DLD 410 _SEEQLK(ac)EEGIEYK_ 1.81
706 IPI00553153 ATPIF1 82 _HHEEEIVHHK(ac)K_ 1.82
707 IPI00554777 ASNS 203 _VASVEMVK(ac)YHHCR_ 1.82
708 IPI00453473 HIST1H4H 9 _GK(ac)GGK(ac)GLGK(ac)GGAK_ 1.85
709 IPI00815713 TCOF1 720 _SVGK(ac)GLQVK_ 1.86
710 IPI00784154 HSPD1 91 _YK(ac)NIGAK_ 1.87
711 IPI00021338 DLAT 466 _ELNK(ac)ILEGR_ 1.88
712 IPI00011307 MTHFD2 50 _LAQQIK(ac)QEVR_ 1.88
713 IPI00644322 PHF15 48 _CSK(ac)LPSSTK(ac)SGWPR_ 1.89
714 IPI00926977 PSMC6 220 _VVSSSIVDK(ac)YIGESAR_ 1.89
715 IPI00294779 VDAC3 15 _AAK(ac)DVFNK_ 1.89
716 IPI00006579 COX4I1 53 _DHPLPEVAHVK(ac)HLSASQK_ 1.89
717 IPI00017802 AUH 100 _AYGK(ac)NSLSK_ 1.90
718 IPI00784154 HSPD1 87 _SIDLK(ac)DK_ 1.90
719 IPI00296337 PRKDC 1057 _SPVNTK(ac)SLFK_ 1.92
720 IPI00384428 BPHL 271 _LHLMPEGK(ac)HNLHLR_ 1.92
721 IPI00654555 NSUN2 71 _SPEAK(ac)PLPGK_ 1.92
722 IPI00026516 OXCT1 421 _MVK(ac)GMGGAMDLVSSAK_ 1.92
723 IPI00220487 ATP5H 72 _AGLVDDFEK(ac)K_ 1.92
724 IPI00513827 ACADM 312 _VAMGAFDK(ac)TRPVVAAGAVGLAQR_ 1.93
725 IPI00020602 CSNK2A2 103 _LIDTVK(ac)DPVSK_ 1.94
726 IPI00017283 IARS2 189 _SFAK(ac)AAIEK_ 1.94
727 IPI00784154 HSPD1 364 _GKGDK(ac)AQIEK_ 1.94
728 IPI01018954 HADHB 271 _LK(ac)PAFIK_ 1.95
729 IPI00291006 MDH2 329 _K(ac)GEDFVK_ 1.95
730 IPI00419802 HIBCH 360 _WK(ac)PADLK_ 1.97
731 IPI00220362 HSPE1 86 _VVLDDK(ac)DYFLFR_ 1.97
732 IPI00983068 TXNRD1 245 _VEETVK(ac)HDWDR_ 1.98
733 IPI00915363 RPS24 37 _ATVPK(ac)TEIR_ 1.98
734 IPI00304925 HSPA1A 328 _LDK(ac)AQIHDLVLVGGSTR_ 1.99
735 IPI00420108 DLST 267 _HK(ac)EAFLK_ 2.00
736 IPI00554525 NHS 1519 _K(ac)SNTSNEEFK(ac)LLLLK(ac)K_ 2.00
737 IPI00554525 NHS 1510 _K(ac)SNTSNEEFK(ac)LLLLK(ac)K_ 2.00
738 IPI00554525 NHS 1524 _K(ac)SNTSNEEFK(ac)LLLLK(ac)K_ 2.00
739 IPI00216308 VDAC1 20 _DVFTK(ac)GYGFGLIK_ 2.01
740 IPI00001539 ACAA2 270 _K(ac)HNFTPLAR_ 2.01
741 IPI00007765 HSPA9 567 _NAEK(ac)YAEEDRR_ 2.03
742 IPI00019755 GSTO1 160 _LEEVLTNK(ac)K_ 2.04
743 IPI00220487 ATP5H 149 _K(ac)YPYWPHQPIENL_ 2.04
744 IPI00742682 TPR 713 _SQNTK(ac)ISTQLDFASK_ 2.05
745 IPI00215777 SLC25A3 98 _MQVDPQK(ac)YK_ 2.06
746 IPI01018954 HADHB 250 _VPGK(ac)DTVTK_ 2.07
747 IPI00001734 PSAT1 378 _ALELNMLSLK(ac)GHR_ 2.10
748 IPI00783097 GARS 219 _ADHLLK(ac)AHLQK_ 2.10
749 IPI00815713 TCOF1 637 _PALK(ac)IPQTK_ 2.11
750 IPI00031522 HADHA 505 _VIGMHYFSPVDK(ac)MQLLEIITTEK_ 2.12
751 IPI00784154 HSPD1 130 _EGFEK(ac)ISK_ 2.14
752 IPI00101664 NARS2 353 _TEHEK(ac)YLVK_ 2.14
753 IPI00337494 SLC25A24 228 _IMMQVHGSK(ac)SDK_ 2.16
754 IPI00099433 MYST4 1042 _VQSK(ac)NK(ac)YLHSPESR_ 2.18
755 IPI00022314 SOD2 68 _HHAAYVNNLNVTEEK(ac)YQEALAK_ 2.21
756 IPI00027107 TUFM 350 _PGSIK(ac)PHQK_ 2.21
757 IPI00298961 XPO1 693 _QLGSILK(ac)TNVR_ 2.22
758 IPI00908949 TARS 582 _IDIQIK(ac)DAIGR_ 2.23
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759 IPI00298406 HADH 317 _GDASK(ac)EDIDTAMK_ 2.23
760 IPI00553185 CCT3 222 _GVMINK(ac)DVTHPR_ 2.25
761 IPI00220362 HSPE1 70 _VGDK(ac)VLLPEYGGTK_ 2.26
762 IPI00007765 HSPA9 135 _YDDPEVQK(ac)DIK_ 2.28
763 IPI00925052 ARC20 108 _ILCHK(ac)FMR_ 2.31
764 IPI00030363 ACAT1 174 _GSTPYGGVK(ac)LEDLIVK_ 2.33
765 IPI00553153 ATPIF1 71 _EQLAALK(ac)K_ 2.34
766 IPI00007765 HSPA9 288 _HIVK(ac)EFK_ 2.35
767 IPI00744711 PNPT1 285 _LFTPSPEIVK(ac)YTHK_ 2.37
768 IPI00008752 MT1G 57 _GASEK(ac)CSCCA_ 2.38
769 IPI00939954 MT2A 56 _GASEK(ac)CSCCA_ 2.38
770 IPI00008528 ATP8 40 _MLNTNYHLPPSPK(ac)PMK_ 2.39
771 IPI00022314 SOD2 130 _DFGSFDK(ac)FK_ 2.41
772 IPI00018206 GOT2 90 _KAEAQIAAK(ac)NLDK_ 2.46
773 IPI00337494 SLC25A24 336 _ILK(ac)HEGLGAFYK_ 2.57
774 IPI00332082 ATXN7 678 _SSK(ac)SLRPK_ 2.64
775 IPI00022498 MT2A 56 _GASDK(ac)CSCCA_ 2.65
776 IPI00337494 SLC25A24 320 _LAVGK(ac)TGQYSGIYDCAK_ 2.66
777 IPI00007765 HSPA9 600 _MEEFK(ac)DQLPADECNK_ 2.68
778 IPI00007765 HSPA9 300 _ETGVDLTK(ac)DNMALQR_ 2.72
779 IPI00006579 COX4I1 60 _HLSASQK(ac)ALK_ 2.73
780 IPI00001539 ACAA2 137 _FGTK(ac)LGSDIK_ 2.92
781 IPI00007765 HSPA9 612 _LK(ac)EEISK_ 2.97
782 IPI00071703 GFM2 265 _TFK(ac)GVVDVVMK_ 3.15
783 IPI00006077 PHF16 30 _IK(ac)SK(ac)IPNEHK_ 3.17
784 IPI00006077 PHF16 32 _IK(ac)SK(ac)IPNEHK_ 3.17
785 IPI00300567 DCI 89 _LENDK(ac)SFR_ 3.32
786 IPI00985353 EEF1D 433 _FK(ac)YDDAER_ 3.48
787 IPI00018206 GOT2 396 _LIK(ac)EFSIYMTK_ 3.58
788 IPI00748731 C1orf222 257 _FLK(ac)ASLGR_ 4.31
789 IPI00465315 CYCS 87 _MIFVGIK(ac)K_ 4.47
790 IPI00220327 KRT1 376 _SKAEAESLYQSK(ac)YEELQITAGR_ 7.53
791 IPI00297683 PACRGL 206 _HLLTSLSK(ac)R_ 9.77
Non-Quantiﬁable
792 IPI00023006 ACTC1 86 _YPIEHGIITNWDDMEK(ac)IWHHTFYNELR_
793 IPI00003815 ARHGDIA 127 _EIVSGMK(ac)YIQHTYR_
794 IPI00014230 C1QBP 91 _AFVDFLSDEIK(ac)EER_
795 IPI00396341 C2orf67 859 _AYSK(ac)NVEGQDLLLK_
796 IPI00903296 CDC42BPA 1194 _ILK(ac)K(ac)NK(ac)FR_
797 IPI00903296 CDC42BPA 1191 _ILK(ac)K(ac)NK(ac)FR_
798 IPI00903296 CDC42BPA 1192 _ILK(ac)K(ac)NK(ac)FR_
799 IPI00025366 CS 459 _SMSTEGLMK(ac)FVDSK_
800 IPI00003944 DBT 440 _GEVYK(ac)AQIMNVSWSADHR_
801 IPI00186290 EEF2 638 _YLAEK(ac)YEWDVAEAR_
802 IPI00010810 ETFA 69 _VAQDLCK(ac)VAGIAK_
803 IPI00018206 GOT2 404 _EFSIYMTK(ac)DGR_
804 IPI01018954 HADHB 50 _TPFLLSGTSYK(ac)DLMPHDLAR_
805 IPI00026272 HIST1H2AB 96 _NDEELNK(ac)LLGR_
806 IPI00027230 HSP90B1 479 _IADDK(ac)YNDTFWK_
807 IPI00784154 HSPD1 551 _TALLDAAGVASLLTTAEVVVTEIPK(ac)EEK_
808 IPI00024975 KIF15 1258 _SK(ac)IVEEM(ox)LK(ac)M(ox)K(ac)ADLEEVQSALYNK_
809 IPI00024975 KIF15 1265 _SK(ac)IVEEM(ox)LK(ac)M(ox)K(ac)ADLEEVQSALYNK_
810 IPI00024975 KIF15 1267 _SK(ac)IVEEM(ox)LK(ac)M(ox)K(ac)ADLEEVQSALYNK_
811 IPI00220327 KRT1 185 _EREQIK(ac)SLNNQFASFIDK(ac)VR_
812 IPI00220327 KRT1 197 _EREQIK(ac)SLNNQFASFIDK(ac)VR_
813 IPI00015117 LAMC2 893 _HM(ox)DEFK(ac)RTQK_
814 IPI00015838 LYAR 119 _FQNWM(ox)K(ac)NSLK(ac)VHNESILDQVWNIFSEASNSEPVNK(ac)EQDQR_
815 IPI00015838 LYAR 148 _FQNWM(ox)K(ac)NSLK(ac)VHNESILDQVWNIFSEASNSEPVNK(ac)EQDQR_
816 IPI00015838 LYAR 123 _FQNWM(ox)K(ac)NSLK(ac)VHNESILDQVWNIFSEASNSEPVNK(ac)EQDQR_
817 IPI00011201 ME2 240 _TQQYDDLIDEFMK(ac)AITDR_
818 IPI00016074 MPHOSPH6 11 _LSK(ac)NLLRM(ox)K_
819 IPI00300127 NAT10 1016 _ETKNK(ac)KDM(ox)K_
820 IPI00299571 PDIA6 137 _VGAVDADK(ac)HHSLGGQYGVQGFPTIK_
821 IPI00026519 PPIF 86 _ALCTGEK(ac)GFGYK_
822 IPI00024919 PRDX3 91 _DLSLDDFK(ac)GK_
823 IPI00002922 TBL1XR1 288 _GNFILSAGVDK(ac)TTIIWDAHTGEAK_
824 IPI00815713 TCOF1 155 _TVANLLSGK(ac)SPR_
825 IPI00065671 UCK2 73 _VLTSEQK(ac)AK_
826 IPI00294779 VDAC3 64 _YK(ac)VCNYGLTFTQK_
827 IPI00000875 344 _STFVLDEFK(ac)R_
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cells were infected. Infection state was monitored by an immuno-
ﬂuorescence assay which stained for BDV-speciﬁc nucleoprotein
p40. The now persistently-infected OL cells (OL/BDV cells) and
non-infected OL cells (control cells) were kept under identical
conditions for the remainder of the study.
Cell culture and labeling
We applied a protocol which has been previously adapted and
optimized (Liu et al., 2014a, 2014b). To proﬁle protein Kac in response
to BDV infection, OL/BDV cells were maintained in SILAC medium
containing light isotopic forms of lysine (12C), while control cells were
maintained in SILAC medium containing heavy isotopic forms of lysine
(13C). Brieﬂy, OL/BDV cells and control cells were labeled by the SILAC
Protein Quantitation Kit (Invitrogen, Carlsbad, CA) according to manu-
facturer's instructions. OL/BDV and control cells were separately grown in
DMEM supplemented with 10% FBS and either the light isotopic forms of
[U-12C6]-L-lysine or the heavy isotopic forms of [U-13C6]- L-lysine,
respectively. After six generations of passaging, the heavy labeling
efﬁciency of [U-13C6]-L-lysine in control cells was evaluated by mass
spectrometric analysis to conﬁrm a greater than 99% labeling efﬁciency.
Then, cells were continuously expanded in SILAC medium until reaching
the desired population size. Finally, cells in each heavy- or light-labeled
pool were harvested separately and combined in equal amounts.
Preparation of cell lysates
Cells were harvested and washed twice with cold PBS. The cells
were lysed in 2 NETN buffer (40 mM Tris, pH 8.0, 200 mM NaCl,
Table 2
Acetylated proteins in the ribosomal and proteasomal networks.
Protein IPI ID Protein name L/H ratio MCODE score
Ribosomal network
IPI00003918 RPL4 1.65 18.90952381
IPI00000494 RPL5 1.03 18.90952381
IPI00419880 RPS3A 0.92 18.90952381
IPI00376798 RPL11 0.91 18.90952381
IPI00221088 RPS9 0.65 18.90952381
IPI00010153 RPL23 0.95 18.90952381
IPI00219156 RPL30 0.91 18.90952381
IPI00026202 RPL18A 0.74 18.90952381
IPI00719752 EIF3B 0.96 17
IPI00915363 RPS24 1.98 18.90952381
IPI00013415 RPS7 1.08 18.90952381
IPI00470528 RPL15 0.95 19
IPI00299573 RPL7A 1.00 18.90952381
IPI00179330 RPS27A 0.84 19
IPI00217030 RPS4X 1.11 18.90952381
IPI00219160 RPL34 1.71 18.90952381
IPI00465361 RPL13 1.18 18.90952381
IPI00794659 RPS20 0.90 18.90952381
IPI00028635 RPN2 1.74 16
IPI00186290 EEF2 1.28 18
IPI00221089 RPS13 1.25 18.90952381
IPI00555744 RPL14 1.34 18.90952381
IPI00867533 RPL6 0.91 18.90952381
IPI00456429 UBA52 0.88 18.90952381
Proteasomal network
IPI00926977 PSMC6 1.89 4.761904762
IPI00027626 CCT6A 1.14 5
IPI00216247 PSMD4 0.88 5
IPI00297779 CCT2 0.96 5
IPI00003865 HSPA8 1.20 5
IPI00019927 PSMD7 1.01 4.761904762
IPI00419249 PSMA3 0.80 4.761904762
IPI00553185 CCT3 2.25 5
IPI00220362 HSPE1 2.26 5
IPI00784090 CCT8 1.23 5
IPI01024911 PSMA7 1.13 4.761904762
Fig. 2. Ribosomal and Proteasomal Networks.
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Fig. 3. Enrichment and Clustering Analysis of the Kac Datasets based on Gene Ontology Annotations Quantiﬁable proteins were classiﬁed by gene ontology (GO) annotation
based on (A) biological process, (B) molecular function, and (C) cellular compartmentalization. In each GO category, the differential quantiﬁable proteins were divided into four
quantiles based on the cumulative distribution of SILAC L/H ratios: Q1, less than 15%; Q2, 15–30%; Q3, 70–85%; and Q4, greater than 85%. An enrichment analysis was separately
performed in each quantile for diverse categories, and the overrepresented annotations were clustered through one-way hierarchical clustering for comparative analysis.
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2 mM EDTA,1% NP40) on ice for 20 min. Cell lysates were centrifuged
at 16,000 g for 15 min at 4 1C. The supernatant was collected as an
NETN-soluble fraction, and the pellet was further lysed by SDS buffer
(containing 62.5 mM Tris–HCl at pH 6.8 and 2% SDS) and sonication
to generate an NETN-pellet fraction. Protein concentrations were
measured using the Bradford assay. Equal amounts of protein from
the NETN-soluble fractions of OL/BDV cells and control cells were
mixed and separated on preparative HPLC into 20 fractions using a
Fig. 4. Enrichment and Clustering Analysis of Kac Substrate Proteins Based on Protein Domains, Cellular Pathways, and Protein Complexes Genes were annotated based on
(A) the PFAM domain database, (B) the KEGG pathway database, and (C) the CORUM protein complex database. The analysis was performed as described in Fig. 2. In addition,
k-means clustering was used to identify BDV-regulated human protein complexes.
Table 3
Main results of GO analysis, protein domain, KEGG pathway and protein complex.
Q1(the quantile with low L/H ratio) Q4 (the quantile with high L/H ratio)
GO-biological
process
Cell differentiation and development, neurogenesis,
nervous system development
Diverse metabolic processes
Phosphate-containing compound metabolic process, nucleoside phosphate metabolic process,
cellular lipid metabolic process, cellular amino acid metabolic process, organophosphate












Nuclear receptor coactivator, Zinc ﬁnger, Coactivator CBP
and Bromodomain
Diverse metabolic enzymes (i.e., FAD/NAD linked reductase, 3hydroxyacylCoA
dehydrogenase, Thiolase, Pyridine nucleotidedisulphide oxidoreductase, Crontonase,









PA700–20S-PA28 complex, PA28–20S proteasome,
PA28gamma-20S proteasome and 26S proteasome
F1F0ATP synthase (EC 3.6.3.14), mitochondrial
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polyCAT/WAX ion exchange column (Shimadzu, Kyoto, Japan). Pro-
teins from each HPLC fraction were precipitated using TCA/acetone.
The resulting protein precipitate was washed twice with ice-cold
acetone and stored at -20 1C before in-solution digestion with
trypsin.
In-solution digestion of proteins and enrichment of lysine-acetylated
peptides
The precipitated proteins were digested with trypsin using a
procedure previously described (Kim et al., 2006b). To enrich Lys-
acetylated peptides, the trypic digest in NETN buffer (100 mM
NaCl, 1 mM EDTA, 50 mM Tris–HCl, 0.5% NP-40, pH 8.0) was
incubated with anti-acetyllysine agarose beads (PTM Biolab, Chi-
cago, IL) at 4 1C for 4 h with gentle shaking. The beads were
washed four times with 1 ml of NETN buffer and twice with
ddH2O. The bound peptides were eluted from the beads with 1%
triﬂuoroacetic acid. The eluted fractions were combined and dried
in a SpeedVac (ThermoFisher Scientiﬁc, Waltham, MA). The pep-
tides from the NETN-soluble fractions were analyzed by high-
performance liquid chromatography tandem mass spectrometry
(HPLC-MS/MS), while the peptides from the NETN-pellet fractions
were resolved into 12 fractions in a 3100 OFFGEL Fractionator
(Agilent Technologies, Santa Clara, CA) according to the manufac-
turer's instructions. Each fraction was cleaned in a C18 ZipTip
(Millipore, Billerica, MA) prior to HPLC-MS/MS analysis.
LC-ESI-MS/MS analysis by Q exactive
The peptides were resuspended in buffer A (2% ACN, 0.1% FA)
and centrifuged at 20,000 g for 2 min. The supernatant was
transferred into a sample tube and loaded onto an Acclaim
PepMap 100C18 trap column (Dionex, 75 μm2 cm) by EASY
nLC1000 nanoUPLC (ThermoFisher Scientiﬁc, Waltham, MA). The
peptide was eluted from an Acclaim PepMap RSLC C18 analytical
column (Dionex, 50 μm15 cm). A 34-min gradient was run at
300 nl/min, starting from 5% to 30% B (80% ACN, 0.1% FA), followed
by 2 min linear gradient to 40% B, then 2 min to 80% B, and
maintenance at 80% B for 4 min.
The peptides were subjected to NSI source followed by MS/MS in Q
Exactive (ThermoScientiﬁc, CA, USA) coupled online to the UPLC. Intact
peptides were detected in the Orbitrap at a resolution of 70,000.
Peptides were selected for MS/MS using 25% NCE with 4% stepped
NCE; ion fragments were detected in the Orbitrap at a resolution of
17,500. A data-dependent procedure that alternated between one MS
scan followed by 15 MS/MS scans was applied for the top 15 precursor
ions above a threshold ion count of 4E4 in the MS survey scan with
2.5 s dynamic exclusion. The electrospray voltage applied was 1.8 kV
automatic gain control (AGC) was used to prevent overﬁlling of the ion
trap; 2E5 ions were accumulated for each generation of MS/MS
spectra. For MS scans, the m/z scan range was 350-1800 Da.
SILAC-based quantiﬁcation analysis
The Kac site identiﬁcation and quantiﬁcations were performed by
MaxQuant with the integrated Andromeda search engine (v. 1.3.0.5).
For each MS/MS spectra, the top 10 most intense peaks in every
100 Da window were extracted. Then, tandem mass spectra were
searched against the Swissprot human protein database concate-
nated with the reverse decoy database and protein sequences of
common contaminants.
Trypsin/P was speciﬁed as the cleavage enzyme with 3 max
missing cleavages, 4 max labeled amino acids, and 4 max number of
modiﬁcations per peptide. Mass error was set to 6 ppm for
precursor ions and 0.02 Da for fragment ions. Carbamyliodomethy-
lation on Cys was speciﬁed as a ﬁxed modiﬁcation and oxidation on
Met, and acetylation on Lys, and protein N-terminals were speciﬁed
as variable modiﬁcations. False discovery rate (FDR) thresholds for
protein, peptide, and Kac sites were speciﬁed at 0.05. Minimum
peptide length was set at 7. All the other parameters in MaxQuant
were set to default values. Kac site identiﬁcations with localization
probabilities less than 0.75 or those from reverse or contaminant
protein sequences were removed.
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